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Abstract 
Multi-drug resistance or MDR is a major impediment to the successful 
administration of chemotherapy. Broadly defined, the term MDR applies to any 
mechanism the cell uses to counter the effects of chemotherapeutic agents, 
protecting the cell at once against the toxicity of many, structurally dissimilar 
compounds. There are several routes to MDR for a cell, and they include 
everything from decreasing intracellular drug concentrations to increasing rates of 
drug metabolism. The study presented here focuses on the role of drug 
transporters in conferring drug resistance. MDR transporters are traditionally 
thought to extrude cytotoxins from the cell at the plasma membrane, and they 
thereby serve as a permeability barrier for drug entry into the cell. Several MDR 
transporters have been cloned to date, but this study focuses on the functional 
characterization of one of these proteins, the human multidrug resistance protein 1 
or MRP 1. 
MRP1, like other members of the MDR transporter family, is thought to 
be expressed at the plasma membrane and decrease the intracellular accumulation 
of many different chemotherapeutic compounds. Unlike other MDR transporters, 
however, MRP 1 is thought to require reduced glutathione to enable the transport 
of most of its chemotherapeutic substrates. Using a fluourescently tagged MRP1 
protein, we make two novel demonstrations: that MRP1 can contribute to a drug 
resistance phenotype from intracellular membranes, as well as from the plasma 
membrane; and two, that MRP1 is active in the absence of glutathione. 
Chapter 1 Introduction to Multidrug Resistance 
Chapter One: A Brief Introduction to Multi-drug Resistance and the 
A B C transporter family 
1.1 Multi-drug Resistance Defined 
Cellular multi-drug resistance or MDR is a significant obstacle to the 
successful administration of chemotherapy. Broadly defined, the term MDR 
applies to any mechanism the cell uses to counter the effects of chemotherapeutic 
agents, protecting the cell at once against the toxicity of many, structurally 
dissimilar compounds. There are several routes to MDR for a cell, and they 
include everything from decreasing intracellular drug concentrations to increasing 
rates of drug metabolism (see two recent reviews (Gottesman, 2002;Gottesman et 
al, 2002)). I will briefly give an overview of the cellular mechanisms of 
acquiring drug resistance, organizing the discussion under two general 
subheadings: one, diminishing drug availability to cellular targets, and two, 
altering drug sensitivity. 
Decreasing the availability of drugs to their cellular targets can occur 
simply by reducing the rates of drug entry. For drugs that enter cells by passive 
diffusion, for example, structural changes at or near the plasma membrane can 
alter rates of drug entry. Recent research into drug resistance in polarized 
epithelial cells, for example, suggests that barriers to drug diffusion are created in 
an "entrance compartment" by micro-villi and an associated actin cytoskeleton 
(Lange and Gartzke, 2001). For those drugs that enter cells by utilizing existing 
cellular machinery, decreases in drug uptake can occur either as a result of 
changes in the endocytic pathway or in plasma membrane receptors. Resistance 
to the anti-folate drug methotrexate, for example, often occurs as a result of 
mutations in the two transporters responsible for folate uptake, transporters co-
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opted by the drug to enter the cell (for a review, see Cancer, Principles 
and Practices of Oncology). Decreased drug presentation can also occur if the 
drug is sequestered away from cellular targets once it has entered the cell. The 
chemotherapeutic doxorubicin, for instance, accumulates in the lysosomes of drug 
resistant cells, and is thus kept from the nucleus, where it is known to induce 
apoptosis by damaging DNA (Schindler et ai, 1996;Hurwitz et al, 1997). 
Finally, drugs can be less available at their cellular targets because they are 
effluxed from the cell upon entry. Drug efflux pumps like the well studied P-
glycoprotein are expressed at the plasma membrane and actively extrude 
chemotherapeutics in an ATP-requiring transport event. Transporters like P-
glycoprotein will be the subject of this study and will be discussed subsequently 
in further detail. 
Under the second subheading of acquiring MDR, we find all the methods 
available to the cell to reduce cellular sensitivity to MDR agents. Increasing rates 
of DNA repair, for example, or inhibiting apoptosis, both increase survival rates 
in response to chemotherapeutics. Drugs can also be metabolized, thereby 
altering their toxicity. Cisplatin resistance, for example, is associated with 
increases in the expression of the gene encoding glutathione-S-transferase 
71 (GST). Moreover, GST-mediated glutathione conjugation is frequently 
associated with drug resistance to alkylating compounds like melphalan 
(Yokomizo et al, 1995), as well as many other electrophilic chemotherapeutics 
(Morrow et al, 1998). Other detoxification pathways exist, and are broadly 
classified under two general categories: Phase I detoxification, in which a 
functional group is added or exposed (usually via a cytochrome P-450 enzyme) or 
Phase II detoxification, in which drugs undergo conjugation reactions via 
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glutathionation, sulfonation, acetylation or methylation (see Cancer, 
Principles and Practices of Oncology). Finally, cells can become MDR by 
altering their sensitivity to the anti-proliferative nature of chemotherapeutic 
agents, with less stringent cell cycle regulation, for example. 
1.2 ABC transporters and Multi-drug resistance 
To date, 48 human transporters belonging to the ATP-binding cassette 
(ABC) family of proteins have been identified (Muller, 2003), and a number of 
them have been implicated in the development of multi-drug resistance. These 
transporters confer drug resistance by actively extruding chemotherapeutic 
compounds from the cell, in an ATP-dependent manner. The first and probably 
most well characterized ABC protein involved in acquiring MDR is P-
glycoprotein, encoded by the multidrug resistance 1 (MDR1) gene. Over-
expression of the cDNA encoding P-glycoprotein is sufficient to confer drug 
resistance to many structurally unrelated cytotoxins, including those administered 
in chemotherapy, like the anthracyclines, the vinca-alkaloids, and colchicine 
(Gros et al, 1986;Chen and Simon, 2000). P-glycoprotein (Pgp) is a 170-kDa 
protein, expressed in the apical membrane of polarized cells, whose expression 
can be inversely correlated with the successful administration of chemotherapy 
(Chan et al, 1991). Structurally, Pgp and other members of the ABC family 
generally consist of a core of 12 transmembrane domains and two nucleotide 
binding domains, although there are some notable exceptions (Borst and Elferink, 
2002). The breast cancer resistance protein or BCRP, for example, is a half 
transporter, and consists of only 6 transmembrane domains and one nucleotide 
binding domain. The multi-drug resistance protein 1, as well as other members of 
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the MRP family, have a core structure similar to Pgp, with a 280 amino 
acid N-terminal extension (Bakos et al, 1998). However, what these MDR-
conferring ABC proteins all share is the ability to significantly reduce the 
intracellular concentration of many structurally unrelated compounds when over-
expressed at the cell surface. 
1.3 MRP1 
Human MRP1, or the multidrug associated protein 1, is a 190-kDa 
member of the ABC family of transporters. The gene encoding MRP1 is to be 
found on chromosome 16; it spans 200 kb minimally and includes 31 exons, as 
well as multiple class 0 introns (Grant et al, 1997). As its name suggests, the 
protein is thought to be responsible for conferring multidrug resistance in a 
variety of cancers and has, like Pgp, become a major obstacle to the successful 
administration of chemotherapy. First cloned in 1992 from a daunorubicin 
resistant lung cancer cell line (Cole et al, 1992), MRP1 has since been associated 
with increased resistance to doxorubicin, vincristine, VP16, and colchicine. 
MRP1 is expressed ubiquitously throughout the body (Borst et al, 2000), and 
MRP1 mRNA has been found in a large variety of tumor types (Hipfner et al, 
1999). Moreover, increased expression of the transporter has been shown to 
correlate with poor clinical outcomes (Hipfner et al, 1999). 
Physiologically, MRP1 is thought to extrude the cysteinyl leukotriene 
LTC4 from the cell, as well as other conjugated organic anions. Its ability to 
transport LTC4 has suggested a role for MRP1 in mediating the migration of 
dendritic cells to the lymph nodes, as extrusion of LTC4 in these cells is necessary 
for chemotaxis to the chemokine CCL19 (Robbiani et al, 2000). Its transport of 
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LTC4 has also implicated MRP1 in regulating inflammation in tissues, as 
MRP1 null mice were deficient in both LTC4 transport, as well as LTC4-
dependent inflammatory responses (Wijnholds et al, 1997). Additionally, 
MRP 1-mediated LTC4 transport has been found to correlate with increased 
sensitivity to Streptococcus pneumoniae, as increased intracellular concentrations 
of LTC4 negatively regulate LTC4 biosynthesis, and thereby increase production 
of another cysteinyl leukotriene LTB4, an important elicitor of microbiocidal 
responses in phagocytic cells (Schultz et al, 2001). 
Despite these physiological roles, mrpl null mice are viable, fertile, and 
show no developmental phenotypes or discernable changes in body or organ 
morphology (Wijnholds et al, 1997). However, these mice have substantially 
increased sensitivities to MDR drugs like VP16 and vincristine (the latter only in 
isolated bone marrow derived mast cells). As a result of exposure to etoposide-
phosphate, mrpl null mice show extensive damage in the oropharyngeal mucosal 
layer, the testicular tubules, and the choroid plexus epithelium, suggesting that the 
protein actively protects against xenobiotic agents in these tissues (Wijnholds et 
al, 1998;Wijnholds et al, 2000). Mouse mrpl is also thought to contribute to the 
blood brain drug permeability barrier (Wijnholds et al, 2000). 
1.4 Contextualizing our present study 
Despite these many and substantial advances in our understanding of 
MRP1 activity, both in normal and in patho-physiology, many avenues still 
remain open for MRP1 studies. Previous biochemical and whole cell 
investigations of MRP 1, for example, have produced a number of inconsistent 
reports of MRP 1 substrate specificity and activity in general. Some in vivo 
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studies have found MRP1 to be functional in intracellular compartments 
(Tommasini et al, 1996), while others have seen MRP1 active primarily at the 
plasma membrane. Some studies have suggested MRP1 to be active against 
mitoxantrone, cadmium, vinblastine, and colchicine (Tommasini et al, 1996), 
while others have found MRP1 to confer no increased resistance to these 
compounds. Some of these inconsistencies may be due to the different cell lines 
used to study MRP1; many no doubt are due to the culture conditions used to 
model in vivo MRP1 activity. Cells are either continuously cultured in 
chemotherapeutic agents or selected in antibiotics to ensure MRP1 expression. 
These culture conditions have been shown to result in massive physiological 
changes in the cell, including the up-regulation of DNA repair enzymes, the 
down-regulation of apoptotic machinery, resulting in the generation of 
multifactorial drug resistance (Chen and Simon, 2000). Therefore, the changes 
induced by drug selection could not be distinguished from the effect of MRP 1 
expression. 
For all these reasons, we have developed a means of studying MRP1 
activity in whole cells without protracted drug selection. We have created a GFP 
fusion construct which tags the C terminus of MRP 1 and permits easy 
identification of MRP 1 expression in cells. The fusion protein additionally allows 
us to correlate degrees of MRP 1 expression with GFP fluorescence, and thereby 
makes direct studies of MRP 1 activity possible. By comparing cells transiently 
transfected with the MRP 1-EGFP fusion construct to their non-transfected 
counterparts, we can assess the immediate effect that MRP1 introduction has on a 
cell's drug resistance properties. Transient transfection with the MRP 1-EGFP 
fusion construct obviates the need for protracted propagation in antibiotics and 
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product guidelines. To increase the transfection efficiencies of primary 
and embryonic stem cell lines, endotoxin free DNA was used; endotoxin-free 
DNA was purified using the Endo-free plasmid purification kit from Qiagen. 
2.2 DNA constructs. 
The plasmid encoding synaptotagminVII-ECFP was a gift from Norma 
Andrews, Yale University, New Haven, Connecticut (Litman et al, 2000). The 
plasmid encoding ECFP-CFTR was a gift of David Gadsby, Rockefeller 
University, New York, New York. The pEYFP-ER and the pEYFP-Golgi vectors 
were purchased from BD Biosciences Clontech, Palo Alto, California. 
The construction of the pMDRl-ECFP plasmid has been previously 
described (Chen and Simon, 2000). Briefly, the MDR1-EGFP fusion vector was 
made using site-directed mutagenesis to replace the 3' stop codon with a Sail site. 
The MDR1 open reading frame was then inserted into pEGFP-Nl (Clontech). 
The EGFP coding region was then excised and replaced with ECFP, using Apal 
and BsrGI restriction enzymes. 
BCRP cDNA was a generous gift of Doug Ross, University of Maryland, 
Baltimore, Maryland (Doyle et al, 1998); it was subcloned into the EGFPcl 
plasmid (Clontech) between the EcoRI and Xhol sites. The pECFP-BCRP 
plasmid was made by replacing the EGFP coding sequence with the sequence of 
ECFP. 
Human MRP1 cDNA was obtained in the cloning vector pGEM-1 lZf (gift 
of Gary Kruh, Fox Chase). To generate an expression plasmid for wild-type 
MRP1, designated pMRPl, MRP1 cDNA was subcloned between the Sacl and 
Xbal sites of pEGFP-Nl (Clontech, Palo Alto, CA), a step that excised the EGFP 
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coding sequence and created a pEGFP-Nl-backbone plasmid with 
MRP1 placed under the control of the CMV promoter. To generate the MRP1-
EGFP fusion protein, standard mutagenesis techniques were used on pMRPl to 
replace the MRP1 stop codon with an Agel site, the site at which GFP was 
introduced. pMRPl-ECFP and pMRPl-EYFP were created by replacing EGFP 
with ECFP or EYFP (Clontech). 
2.3 Western blot analysis 
MRP1 and MRP 1-EGFP transfected cells were dissociated with Cell 
Stripper (Cellgro) and solubilized with 1% Triton X-100. The nuclear debris was 
removed by a low speed centrifugation and the supernatant was resolved on a 4-
20% gradient gel, using SDS PAGE. After electro-transfer onto a membrane 
(Amersham Pharmacia Biotech, Piscataway, NJ) using a semi-dry electro-blotter, 
proteins were immunoblotted with either the MRPrl anti-MRP 1 rat monoclonal 
antibody (Alexis Biochemicals, San Diego, CA) and an alkaline phosphatase 
conjugated anti-rat IgG antibody (Sigma) or directly with the alkaline phosphatase 
conjugated Living Colors Peptide Antibody (Clontech). 
2.4 Fluorescence microscopy 
Cells were observed by fluorescent microscopy on fibronectin-coated 
(Sigma) glass bottom culture dishes (MatTek, Ashland, MA). Wide field 
fluorescence microscopy was performed with an IX-70 Olympus microscope 
using a 1.4 N.A. X60 oil-immersion objective, and an ORCA cooled CCD camera 
(Hamamatsu Photonics, Hamamatsu City, Japan) as previously described (Chen 
and Simon, 2000). Wide field fluorescence microscopy with deconvolution was 
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performed using a DeltaVision deconvolution microscope with a 1.4 
N.A. oil-immersion 60X objective. The following excitation and emission filters 
were used for wide-field fluorescent microscopy: CFP: Xex = 400-430 nm, Am = 
460-500 nm; GFP: Ax - 480-490 nm, Xem = 500-550 nm; TMRE: Ax = 530-560 
nm, Xem = 570-650 nm. Confocal microscopy was performed on either an upright 
Axioplan 2 microscope or an inverted Axiovert 100 microscope, each with an 
LSM 510 confocal attachment (Carl Zeiss, Thornwood, NY), using a 1.2 N.A. 
water-immersion 63X objective. The following excitation laser lines and emission 
filters were used: GFP: ^ex = 488 nm, Am = 500-530 nm; daunorubicin, 
doxorubicin: Ax = 488 nm, Am = 580 nm long pass (LP); and mitoxantrone: Ax = 
633 nm, Am - 650 nm LP. 
Fluorescent images were analyzed using MetaMorph software (Universal 
Imaging, Downington, Pennsylvania). To quantify fluorescence intensities on a 
cell-by-cell basis, bright field images were used to acquire the cell boundary, and 
MetaMorph software was used to calculate the average intensity within the 
cellular boundary for each fluorophore. The mean of these averages was 
calculated, along with the standard error. Data was collated and graphed using 
software from Sigma Plot (SPSS Science, Chicago, IL). The degree to which 
different fluorescent markers were said to correlate was determined by the 
correlation co-efficient for any two given fluorophores, where the correlation co-
efficient is an expression of the degree to which the pixel intensities of two 
different fluorophores deviate from each other for a given area within a 
micrograph. Correlation co-efficient calculations were performed using 
MetaMorph software. 
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2.5 Activity Assays and Fluorescence Quantification 
2.5.1 Fluorescent chemotherapeutic reagents 
Tetramethyl rhodamine ester or TMRE was purchased from Molecular 
Probes, Eugene, Oregon. Mitoxantrone was purchased from Sigma. Doxorubicin 
and daunorubicin were purchased from Calbiochem, La Jolla, California. 
MRP1, BCRP, and Pgp activity assays were conducted similarly. 24-48 
hours after transfection, cells expressing fluorescent conjugates of the transporter 
of interest were washed in HHBSS, incubated in either 50 nM TMRE, 1-10 uM 
daunorubicin, 1-1 OuM doxorubicin, or 1-10 uM mitoxantrone for 15 minutes in a 
5% pC02 incubator, and observed by fluorescent microscopy. All 
chemotherapeutic reagents, with the exception of TMRE, were washed out prior 
to observation. 
2.5.2 Non-fluorescent chemotherapeutic reagents 
Vincristine, vinblastine, and colchicine were purchased from Calbiochem. 
Cells expressing fluorescent conjugates of the transporters of interest were 
washed in HHBSS, incubated in 100-600nM vincristine, 100-600nM vinblastine, 
or 2uM colchine for different time intervals in a 5% C02 incubator, then washed 
in HHBSS, and subsequently fixed and immunostained to visualize the 
microtubule cytoskeleton. To visualize microtubules, cells were washed in chilled 
phosphate buffered saline (PBS), permeabilized with ice-cold methanol for 10 
min at 20 °C, washed in ice cold PBS, and immuno-labeled with Cy3-labeled anti-
(3 tubulin antibody (Sigma) according to manufacturer's instructions. 
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2.5.3 Assays for speculated MDR modulators 
Verapamil was used to inhibit MRP1 transport activity at 50uM. Buthione 
sulfoximine (BSO) was purchased from Sigma. Cells were incubated in 25|iM 
BSO for 24 hours prior to assays of MDR transport or intracellular glutathione 
concentration, and was present during all transport assays. 
2.6 Immunocytochemistry. 
For fixation, cells were washed with chilled phosphate buffered saline 
(PBS), permeabilized with ice-cold methanol for 10 min at 20 °C, and rinsed 
twice with cold PBS. To detect MRP1 or cathepsin D, fixed cells were then 
incubated with the anti-MRP 1 antibody MRPlrl at 1:200 or with the anti-
cathepsin D antibody cathepsin D (Ab-2) (Oncogene Research Products, San 
Diego, California) at 1:20 for one hour. Cells were subsequently washed and 
incubated for one hour in anti-rat Alexa594 (Molecular Probes) 1:1,000 for MRP1 
or anti-rabbit fluorescein for cathepsin D imaging. 
To visualize microtubules, MRP1-CFP transfected cells were fixed in 95% 
ethanol for 10 minutes at -20°C, washed in ice cold PBS, and immuno-labeled 
with Cy3-labeled anti-p tubulin antibody (Sigma) according to manufacturer's 
instructions. 
2.7 Crosslinking 
BM[PEO]4 stock was prepared at 28mM in water and used at a hundred 
fold dilution in Hanks buffered saline solution with lOmM Hepes, pH 7.3 
(HHBSS). Cells were exposed to the reagent at 37 °C for 10 minutes. The 
crosslinking reaction was quenched with 50mM L-cysteine in HHBSS (quenching 
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buffer) for 5 mintues at room temperature. Cells were subsequently 
washed with HHBSS and then assayed for MRP1 activity. Crosslinking with 
BMH was performed with a 90mM DMSO stock used at 1/1000X. Once again, 
cells were exposed to BMH for 10 minutes at 37 °C, then resuspended in 
quenching buffer for 5 minutes at room temperature, washed in HHBSS, and then 
assayed for MRP 1 activity. 
2.8 Fluorescent labeling of subcellular compartments. 
In order to label the recycling endosome, cells were incubated with cy3-
transferrin, as previously described (Lampson et al, 2001). In order to label the 
lysosomes, cells were transfected with synaptotagmin VII-ECFP or were probed 
with an anti-cathepsin D antibody. Additionally, Texas Red dextrans were chased 
into the lysosomes as follows: cells were incubated in dextrans for 1 hour at 37 
°C, washed in culture medium, washed again lhour later, and then allowed to 
remain in culture medium for 8-12 hours. 
2.9 Glutathione assays. 
Glutathione assays were performed using the FluoReporter 
Glutathione/Glutathione S-Transferase Assay Kit from Molecular Probes 
(Eugene, Oregon) according to manufacturer's instructions. Briefly, confluent 
cells were dissociated with Cell Stripper (Cellgro) and lysed in a solution 
containing 1% Triton X-100, protease inhibitor and ImM EDTA. Cell lysates 
were then incubated in reaction buffer with kit-provided glutathione S-transferase 
enzyme and pentafluorobenzyl fluorescein for 30 minutes in a 37°C water bath. 
Reaction products were then assessed for fluorescent glutathione adducts using 
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thin layer chromotagraphy (TLC). Samples were dotted onto TLC 
silica gel 60 F254 plates (EM Science, Merk, Darmstadt, Germany), and then these 
plates were placed in a TLC chamber containing 60% 1-butanol, 20% methanol, 
and 20% water. Fluorescent adducts were detected and analyzed using standard 
techniques. This assay is advertised to be sensitive to within lOuM GSH. 
2.10 Flow cytometry 
Flow cytometry was performed on a FACSort (Becton Dickinson, San 
Jose, CA). Adherent cells were non-enzymatically dissociated using Cell Stripper, 
resuspended in Opti-MEM with fluorescent drugs and incubated at 37 °C for 30 
min, and stored on ice until sample acquisition (not more than 30 min). The cells 
were harvested and resuspended in ice-cold PBS with a DNA stain to label dead 
cells [either 10 nM TOTO-3 iodide (Molecular Probes) or 1 uM propidium iodide 
(Sigma)] immediately before data acquisition. The lasers and filters used were: 
GFP: Ax = 488 nm, A,em = 500-520 nm; daunorubicin, doxorubicin, TMRE, 
propidium iodide: Ax = 488 nm, A,em = 564-606 nm; and mitoxantrone, TOTO-3 
Ax = 633 nm, X em = 650 nm LP. 
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3 Chapter 3 Assessments of MRP1-EGFP expression and activity 
3.1 Generation of MRP1-EGFP 
In the first chapter, we discussed some of the different approaches 
available to the study of multiple drug resistance, and particularly, that mediated 
by MRPL The method that we have chosen to employ, fluorescence-based in 
vivo analysis of protein function, requires fluorescent labeling of both MRP1 and 
its drug substrates. A number of MRP 1 substrates are naturally fluorescent and 
therefore could be used to monitor the drug transport activity of the protein. To 
label MRP1 itself with a fluorescent tag, we chose to add the enhanced green 
fluorescent protein to the C-terminus of MRP 1 (Fig. 3-1). Using site-directed 
mutagenesis, we replaced the stop codon of the MRP1 cDNA with a restriction 
site that facilitated the addition of the enhanced green fluorescent protein or EGFP 
(see Materials and Methods). Once the EGFP tag was added to the C-terminus of 
MRP1, substitutions of the EGFP coding region were made which replaced the 
EGFP with the enhanced cyan fluorescent protein (ECFP), the enhanced yellow 
fluorescent protein (EYFP), or Ds Red. 
3.2 Expressing the construct in HeLa cells 
To determine whether the protein would be functional with a fluorescent 
tag, we transfected the MRP 1-EGFP cDNA into HeLa cells, a cell line derived 
from a human, cervical adenocarcinoma. This cell line is easily transfected, 
adheres well to fibronectin-coated glass cover-slips, and, when adherent, exhibits 
a flattened morphology that makes it a good choice for epi-fluorescent 
microscopy. Although HeLa cells do express MRP1 endogenously, this 
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expression is not sufficient to confer drug resistance. For instance, non-
transfected HeLa cells are 5 to 15 fold more sensitive to doxorubicin, 
daunorubicin, vincristine, and VP16 than HeLa cells transfected with, and over-
expressing, MRP 1 (Cole et al, 1994). In our own investigations of non-
transfected HeLa cells, we found that endogenously expressed MRP1 migrated as 
a doublet near the 250 kDa protein marker, a finding in keeping with the 190kDa 
molecular weight reported for MRP1 (Fig. 3-2, a). A similar MRP1 doublet has 
been seen in cells transfected with MRP1 cDNA reference, and this doublet most 
probably represents different glycosylation states of the protein (Bakos et al, 
1996). 
Immunocytochemistry revealed the protein to be at the plasma membrane, 
and in another sub-cellular compartment, a distribution that has also been 
previously reported for the protein (Chang et al, 1997). (Fig. 3-2, b). The sub-
cellular distribution of the protein will be the subject of future chapters. Despite 
this endogenous expression of MRP 1, the HeLa cell line remains sensitive to the 
addition of chemotherapeutics, and exogenous over-expression of the protein 
confers drug resistance and supports enhanced transport of various 
chemotherapeutic agents (Grant et al, 1994). Of course, drug resistance is a 
relative term, and the sensitivity of non-transfected HeLa cells is simply a 
comparative assessment of drug toxicity. Endogenous MRP1 is most probably 
functional in HeLa cells, and the over-expression of this protein confers increased 
drug resistance. Moreover, because the HeLa cell line has been used frequently to 
examine the effects of MRP 1 over-expression, both in vivo and in vitro, the cell 
line was an ideal starting point for our own investigations of MRP1-ECFP activity 
(Leier et al, 1994;Cole et al, 1994;Grant et al, 1994;Leier et al, 1996;Loe et al, 
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1996a;Loe et al, 1996b;Ito et al, 2001;Qian et al, 2001;Rybczynska et 
al, 2001). 
3.3 MRP1-EGFP is expressed in cells as a full-length protein 
HeLa cells were therefore transfected with the MRP 1-EGFP construct and 
examined first for protein expression. As with any fluorescent protein conjugate, 
we had to confirm that the observed fluorescence was from the EGFP-MRP1 
fusion protein rather than a proteolytically cleaved fragment which contained just 
EGFP. In this way, we could ensure that we would not mistake free EGFP or 
partially proteolyzed protein for a full-length construct. We used two methods to 
ascertain whether the EGFP tag could be a reliable marker for MRP1: 
immunocytochemistry and Western blot. For the latter, cells were first 
transfected with MRP 1-EGFP or wild-type MRP1, lysed, and then probed on 
immunoblots for the expression of MRP1 and EGFP (Fig. 3-3, a-b). Once again, 
over-expressed wild-type MRP1 was found to run as a doublet, near the 250-kDa 
marker, much like endogenously expressed MRP1 did (compare Fig 3-2 a, and 
Fig. 3-3, a, left lane). Likewise, the MRP 1-EGFP protein band was also found to 
run as a doublet, but its electrophoretic mobility was slightly retarded relative to 
wild-type MRP1, a finding in keeping with the addition of a 27-kDa EGFP tag to 
MRP1 (Fig. 3-3, a, right lane). Protein fragments were not detectable in either 
lane, suggesting that there was very little protein degradation of either MRP1 or 
MRP 1-EGFP. Probing cell lysates with an anti-EGFP antibody (an anti-Living 
colors peptide antibody) yielded similar results: no protein fragments were 
detectable in MRP 1-EGFP transfected cells, and MRP 1-EGFP ran as a doublet 
near a 250-kDa protein marker (Fig. 3-3, b). 
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Immunocytochemistry of MRP 1-EGFP transfected cells also 
suggested that the EGFP fluorescent marker remained closely associated with 
MRPL We found nearly identical fluorescence distributions for EGFP 
fluorescence as for immunofluorescence against MRP1, when cells were 
transfected with MRP 1-EGFP, and then fixed and labeled with fluorescent anti-
MRP 1 secondary antibodies (Fig. 3-3, c-f). There was no evidence of free EGFP, 
for there was no EGFP fluorescence in the nucleus of MRP 1 -EGFP transfected 
cells (Fig. 3-3, c, truncated arrow), nor was there any cytosolic fluorescence. Free 
EGFP is known to accumulate in the nucleus and the cytosol when it is expressed 
in cells. However, EGFP fluorescence in MRP 1-EGFP transfected cells remained 
primarily at the surface of the cell on the plasma membrane and in a region 
adjacent to the nucleus, a pattern very similar to that seen with endogenously-
expressed, wild-type MRP1 (Fig. 3-2, b). In addition, the anti-MRP 1 label in 
MRP 1-EGFP expressing cells mirrored EGFP fluorescence: the MRP1 label was 
also at the plasma membrane and adjacent to the nucleus (Fig. 3-3, d). The 
merge of anti-MRP 1 fluorescence (red) and EGFP fluorescence (green) revealed 
the extent of their co-localization; the two signals overlapped closely and created 
a more or less yellow image (Fig. 3-3, e). A line-scan of the merged image 
demonstrated the extent to which the two fluorophores had similar distributions 
across a given cell (Fig. 3-3, f). Further investigations of the sub-cellular 
localization of MRP 1-ECFP were conducted, but discussion of this will be saved 
for the following chapter. For now, it is sufficient for us to note that two 
independent assays suggested that the N and C terminii of MRP 1-EGFP were 
always expressed in conjunction, the amino-terminal region of MRP 1 being 
identified by the MRPrl antibody (at amino acids 238-247 (Flens et al, 
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1994;Chang et al, 1997)) and the C-terminus by EGFP fluorescence. 
Thus, it was most likely that MRP 1-EGFP was being expressed in cells as a full 
length protein. 
3.4 Fluorescent MRP1 activity assays 
We now wanted to transfect the fluorescent MRP1 construct into cells and 
assay its transport activity. Our first activity assay was with TMRE, a fluorescent 
MRP1 substrate that enters the mitochondria of living cells. Because the 
fluorescence spectra of TMRE overlaps that of EGFP, we chose to transfect cells 
with MRP 1-ECFP for our initial assessments of protein activity. Transient 
transfection with MRP 1-ECFP resulted in a mixed population of cells: cells that 
expressed MRP 1-ECFP to various degrees (high to low), as well as cells that did 
not express the protein at all. The latter population of cells served as an internal 
control. Relative to this control, the expression of MRP 1-ECFP would result in 
decreased drug accumulation if the protein were active. Cells that expressed the 
fusion protein would be easily detectable by their ECFP fluorescence; if ECFP-
positive cells consistently showed decreased TMRE fluorescence, we would judge 
the transporter to be functional against this substrate. When MRP 1-ECFP 
transfected cells were loaded with TMRE, we found that the protein substantially 
reduced the intracellular accumulation of TMRE at steady-state (Fig. 3-4). In a 
field of transfected cells loaded with TMRE, the cell expressing MRP 1-ECFP and 
visible by ECFP fluorescence (Fig. 3-4, a) was not visible under TMRE 
fluorescence (Fig. 3-4, b). Only the non-MRP 1 expressing cells in the field, those 
not detectable by ECFP fluorescence, were illuminated under TMRE fluorescence 
(Fig. 3-4, b). The merge of the two fluorescent images made this drug 
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accumulation pattern clear: where there was ECFP fluorescence (green), 
there was no TMRE fluorescence (red), and where there was TMRE fluorescence, 
there was no ECFP fluorescence (Fig. 3-4, c). 
Because TMRE is a live stain dye, we wanted to be sure that the absence 
of TMRE fluorescence in MRP 1-ECFP expressing cells was not the result of 
compromised cell viability. We chose therefore to pre-incubate cells with 
verapamil, a known inhibitor of MRP 1 activity, and then assay its effect on 
TMRE accumulation in transfected cells. If MRP 1-ECFP expression were 
simply causing cell death, then the addition of verapamil should have no effect on 
TMRE exclusion in these cells; on the other hand, if TMRE exclusion in MRP1-
ECFP expressing cells had been the result of MRP 1-mediated transport, then the 
inhibition of MRP 1 transport activity by verapamil would promote TMRE 
accumulation in these cells. When MRP 1-ECFP transfected cells were pre-
incubated in verapamil, we saw that MRP 1-ECFP expressing cells (Fig. 3-4, d) 
were no longer able to exclude TMRE (Fig. 3-4, e-f), while non-expressing cells 
still accumulated the drug (Fig. 3-4, e-f). This experiment suggested active 
transport of TMRE by MRP 1-ECFP. 
Once we had established that MRP 1-EGFP was both fully expressed and 
functional, we could now test the activity of the protein against substances that 
were more disputed substrates of MRPL For example, previously published 
reports have suggested MRP1 to be active against the MDR substrates 
mitoxantrone (Morrow et al, 1998), vinblastine, and colchicine, while others 
have found MRP1 to confer no increased resistance to these compounds (Cole et 
al, 1994;Litman et al., 2000). Studies involving the anthracyclines doxorubicin 
and daunorubicn have also suggested seemingly conflicting assessments of MRP 1 
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transport. Although MRP1 expression has been associated with the 
efflux of daunorubicin from cells, MRP 1-expression has not been associated with 
the cellular efflux of doxorubicin, despite the observation that MRP1 expression 
is sufficient to confer doxorubicin resistance (Cole et al, 1991). If MRP1 is not 
conferring cellular resistance against doxorubicin by mediating its transport from 
the cell, then what other resistance mechanisms could it be promoting? We chose 
to investigate these questions next using our fluorescence-based in vivo transport 
assays. 
3.5 The Weak bases doxorubicin, daunorubicin, and mitoxantrone 
We began first with the chemotherapeutic agents daunorubicin, 
doxorubicin, and mitoxantrone. These weakly basic MDR substrates intercalate 
between the bases of DNA, inhibit topoisomerase II activity, and disrupt cellular 
replication (Vincent De Vita et al, 2001). All three compounds are naturally 
fluorescent, and each has been suggested as an MRP1 substrate. In keeping with 
previous reports, we found that MRP 1-EGFP expression substantially reduced the 
intracellular accumulation of daunorubicin. HeLa cells transfected with MRP1-
EGFP and examined under confocal microscopy showed MRP 1-mediated 
reduction in daunorubicin accumulation (Fig. 3-5, a-c), with MRP 1-expressing 
cells (a) almost undetectable under daunorubicin fluorescence (b-c). However, 
drug efflux assays of doxorubicin were more difficult to interpret. The MRP1-
ECFP expressing cells that were exposed to doxorubicin showed no significant 
reduction in drug accumulation relative to non-expressing cells (Fig. 3-5, d-f). 
The three cells in the center of the field in Fig. 3-5 (d), for example, were positive 
for both EGFP and doxorubicin fluorescence (Fig. 3-5, e-f). It is interesting to 
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note, though, that the nuclei of all three of these MRP 1-positive cells 
showed almost no doxorubicin fluorescence. (Fig. 3-5, f, white arrow), while the 
nuclei of non-expressing cells showed a predominantly nuclear accumulation of 
the drug (Fig. 3-5, f, yellow arrow). Since MRP 1-expressing cells have been 
reported to be resistant to the cytotoxic effects of doxorubicin, this decreased 
sensitivity may be the result of altered patterns of drug distribution in these cells, 
rather than the result of increased drug efflux. The nucleus is, after all, the 
primary sub-cellular target of doxorubicin toxicity. This question of MRP 1-
mediated drug resistance will be discussed in greater detail in chapter 5. 
Transiently transfected HeLa cells were next incubated in 2 uM 
mitoxantrone. Cells with elevated MRP 1-EGFP levels (Fig 3-5, g, cell in the 
upper center with an arrow), showed diminished levels of mitoxantrone 
accumulation (Fig. 3-5, h). However, cells with lower levels of MRP1 (bottom 
center of Fig. 3-5, g), had levels of mitoxantrone that were indistinguishable from 
non-expressing cells (Fig. 3-5, h). In the merged image (Fig. 3-5, i), we can 
clearly distinguish a spectrum of drug accumulation that corresponds to the 
degree of MRP 1-EGFP expressed in the cell. This pattern suggests that MRP1 is 
indeed active against mitoxantrone, if not quite as active as against daunorubicin, 
where EGFP fluorescence always correlated with drug exclusion. However, these 
comparisons of MRP 1 activity are over-simplified, based on limited cell samples, 
and highly dependent upon the viewer's visual interpretation of the data. In order 
to facilitate more rigorous comparisons of MRP 1 activity on different substrates, 
we decided to employ another fluorescence-based assay of drug transport, 
fluorescence activated cell sorting or FACS. With FACS, fluorescence 
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measurements are automated, and sample sizes are thereby increased 
many orders of magnitude above those permitted by fluorescence microscopy. 
When FACS-based analyses of MRP 1 activity were conducted on 
daunorubicin, we found that the expression of MRP 1, represented by EGFP 
fluorescence, was associated with decreased drug fluorescence (Fig. 3-6, a). The 
range of MRP 1-EGFP fluorescence varied over 100-fold, and over this range of 
expression, we saw drug reduction that, at its maximum, was slightly greater than 
10 fold over background. Examinations of Pgp-mediated daunorubicin transport 
revealed a nearly identical activity range (Fig. 3-6, b). We next examined MRP1-
mediated doxorubicin transport by FACS, and surprisingly enough, found that 
MRP1 expression had little effect on the total intracellular accumulation of 
doxorubicin (Fig. 3-6, c). This finding is in keeping with our studies of 
doxorubicin transport under confocal microscopy (Fig. 3-5, d-f), and support our 
preliminary hypothesis that MRP1 is altering patterns of intracellular drug 
accumulation, rather than contributing to drug efflux from the cell. Moreover, 
examinations of Pgp found a similar relationship: expression of the transporter did 
not contribute to decreased drug accumulation (Fig. 3-6, d). These data, along 
with the hypothesis that MDR transporters promote drug resistance by means 
other than drug efflux, will be discussed in subsequent chapters. 
Finally, flow cytometry revealed that MRP1 activity against mitoxantrone 
(Fig. 3-6, e) was considerably diminished when compared to daunorubicin (Fig. 
3-6, a). Cells expressing the highest level of MRP 1-EGFP showed considerably 
less than a ten-fold reduction in drug accumulation (Fig. 3-6, e), an activity 
comparable to Pgp-EGFP expressing cells (Fig. 3-6, f). This weak activity may 
account for the differing assessments of mitoxantrone as a substrate of MRPL 
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3.6 Microtubule-disrupting agents. 
Thus far, we had seen that the expression of MRP 1 was capable of 
decreasing the steady-state accumulation of fluorescent chemotherapeutic agents, 
as assayed by their fluorescence. We next wanted to determine whether these 
transport activities would also be able to reduce the cytotoxic effects of 
chemotherapeutic agents and thereby contribute to drug resistance. For this line 
of investigation, we chose to study another class of MDR substrates, microtubule 
depolymerizing reagents like the vinca alkaloids and colchicine. If MRP 1-EGFP 
expression alone mitigated the depolymerizing effects of these reagents, then 
there would be a direct link between the expression of our fluorescent MRP1 
construct and drug resistance. Moreover, we could also try to resolve for 
ourselves the previous controversy in the field regarding the substrate status of 
these drugs. 
In order to proceed with these investigations, we needed a way of making 
the cytotoxic effects of these reagents amenable to fluorescence-based assays of 
MRP1 activity. In short, we needed a reliable method of visualizing microtubules 
after drug incubation. At first, we attempted co-transfections of MRP1-EYFP and 
tau-ECFP, the latter having been used as an indicator of microtubule structure in 
cells previously (Schmoranzer and Simon, Mol. Biol. Cell, in press). However, 
we needed long expression times (24-48 hours post transfection) to ensure 
functional MRPL Unfortunately, these expression times resulted in the severe 
over-expression of tau-CFP; the protein was no longer reliably associated with the 
cytoskeleton and poorly represented the structure of microtubules (Fig. 3-7, a). 
We next chose to fix cells and probe them with an anti-tubulin antibody, a method 
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which yielded more reliable representations of the microtubule 
cytoskeleton. This latter method was sensitive enough to detect elaborate 
microtubule structures, including the microtubule organizing center or MTOC 
(Fig. 3-7, b arrow), a sensitivity necessary for assaying degrees of microtubule 
depolymerization in response to drug addition. In addition, 
immunocytochemistry allowed us to augment our fluorescent assays of MRP 1 
activity with another fluorescent protein: instead of co-transfecting with MRP1-
EYFP and tau-ECFP, we could now follow the fluorescence of MRP1-EYFP and 
Pgp-ECFP and compare in this way the cyto-protective effects each protein 
afforded. 
For these assays, then, one set of HeLa cells was transfected with MRP1-
EYFP, another set was transfected with Pgp-ECFP, and these two sets were plated 
on the same dish for visualization. Cells either expressed MRP1-EYFP, or Pgp-
ECFP, or they expressed no exogenous drug transporter and were therefore our 
control population of cells. When cells transfected and plated in this way were 
exposed to vincristine, and then examined for microtubule depolymerization, we 
found that both MRP1 and Pgp provided substantial chemo-protection against the 
cytotoxicity of vincristine (Fig. 3-8, a-e). The field of cells in Figs. 3a-e shows 
one cell strongly expressing MRP1-EYFP (Fig. 3-8, a), two cells strongly 
expressing Pgp-ECFP (Fig. 3-8, b), and a number of surrounding cells expressing 
neither protein (Fig. 3-8, d). The microtubules of non-expressing cells were 
severely disrupted by vincristine incubation, so much so that they had altered cell 
morphology (Fig. 3-8, d). These cells were round and considerably smaller than 
their MRP1-EYFP or Pgp-ECFP-tagged counterparts. However, the cell 
expressing MRP1-EYFP and the two cells expressing Pgp-ECFP showed 
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relatively little microtubule depolymerization; each cell had an intricate 
microtubule network. The microtubule-organizing center was intact in Pgp-ECFP 
expressing cells but not in the MRP1-EYFP expressing cells. Therefore, MRP1 
provided some protection against the depolymerizing effects of vincristine, if not 
as much as Pgp. 
Next, we assayed the effect of MRP1-EYFP and Pgp-ECFP on colchicine 
toxicity (Fig. 3-8, f-j). Cells incubated in 2 (iM colchicine were unable to 
maintain microtubule integrity in the absence of either multidrug resistance 
protein (Fig. 3-8, i). These cells were only diffusely stained with the anti-tubulin 
antibody, and they showed no discernable microtubule structure. The expression 
of Pgp-ECFP, however, prevented this loss; the ECFP-tagged cell (Fig. 3-8, g) 
had relatively undamaged microtubules, with the MTOC still intact (Fig. 3-8, h). 
Similarly, the two MRP1-EYFP expressing cells (Fig. 3-8, f) had a complex 
network of microtubules with the MTOC quite evident (Fig. 3-8, j). 
Lastly, we examined the effect of expressing MRP1-EYFP on vinblastine 
toxicity, once again in the presence of ECFP-tagged Pgp. The field of cells in 
Figs. 3-8, k-n contained one MRP 1-expressing cell (Fig. 3-8, k), four Pgp-ECFP 
expressing cells (Fig. 3-8,1) and a number of cells expressing neither protein (Fig. 
3-8, n). Cells lacking both multidrug resistance proteins had clearly been affected 
by vinblastine; they had no extant MTOC and considerably disrupted 
microtubules (Fig. 3-8, n). All four cells expressing Pgp-ECFP showed relatively 
undisrupted microtubule structures, with a MTOC somewhat visible in each cell 
(Fig. 3-8, m). In contrast, the cell expressing MRP1-EYFP could not be 
distinguished from the non-expressing cells (Fig. 3-8, o). As evident in the detail 
of the anti-tubulin stained field (Fig. 3-8, o), the center cell with the least 
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microtubule structure was the one transfected with MRPL The adjacent 
cell had only a slightly disrupted MTOC and was also faintly labeled with ECFP-
tagged Pgp. The surrounding cells, which expressed neither MDR protein, had 
microtubules that had been severely damaged by vinblastine. It seems therefore, 
that MRP1, unlike Pgp, provides little to no protection against the effects of 
vinblastine. This differential effect of MRP 1 expression on vincristine and 
vinblastine had been previously reported (Cole et al, 1994). 
3.7 Overview 
In this chapter, we have seen that MRP 1-ECFP can be used as a reliable 
indicator both of MRP 1 localization and activity. The fusion construct allowed us 
to determine if the immediate introduction of MRP 1 altered the cellular response 
to a chemotherapeutic challenge, and it did so in a way that correlated levels of 
MRP 1-EGFP expression to the intracellular concentration of fluorescent 
substrates. After brief incubations in compounds previously reported to be MRP1 
substrates, HeLa cells expressing MRP 1-EGFP were examined for their ability 
either to affect intracellular drug distribution or to mitigate cytotoxic damage. In 
accordance with previous findings, MRP 1-EGFP expression resulted in 
substantially diminished accumulation of TMRE and daunorubicin, and somewhat 
reduced levels of mitoxantrone. However, MRP 1-EGFP had little effect on total 
doxorubicin concentrations inside the cell. Surprisingly, though, cells expressing 
the fusion construct did have significantly lowered doxorubicin fluorescence 
inside the nucleus, a reduction which may be responsible for MRP 1-mediated 
resistance against this chemotherapeutic. Whether this altered nuclear distribution 
points to functional MRP1 away from the plasma membrane will be discussed in 
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subsequent chapters. When MRP1 expression was assayed for its ability 
to protect against the microtubule-depolymerizing effects of three 
chemotherapeutic agents, the protein was found to substantially attenuate the 
damage caused by colchicine, somewhat guard against vincristine-induced 
microtubule disruption, and have no detectable effect against vinblastine. 
cytosol 
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Figure 3-1 Proposed topology of M R P 1 and MRP1-EGFP 
a. A proposed topology of M R P 1 is presented, showing the five trans-membrane 
(TM) domains thought to characterize its N-terminus, the remaining twelve T M 
domains with their nucleotide binding domains (indicated with arrows), and the 
three proposed glycosylation sites at Asn 19, Asn 23, and Asn 1006 (indicated by 
branched symbols), b. A sketch of the protein now with E G F P (in green) added 
to its C-terminus. 







Figure 3-2 Endogenous expression of M R P 1 in HeLa cells. 
a. HeLa cell lysates were probed after S D S page for the expression of endogenous 
M R P 1 on an immunoblot with the M R P 1 antibody MRPrl. Two bands were 
detected near the 250 kDa protein marker, a result consistent with the reported 190 
kDa mass for M R P 1 . The two fragments are thought to represent different 
glycosylation states of the protein, b. HeLa cells were probed for the subcellular 
distribution of endogenous M R P 1 with the MRPrl antibody. M R P 1 was found at the 
plasma membrane and in a sub-cellular compartment. 
Figure 3-3 MRP1-EGFP transfected HeLa cells over-express full length MRP1-EGFP. 
a-b. In lanes loaded with MRP1-EGFP transfected cell lysates, both an anti-MRP1 and an 
anti-GFP antibody recognized a doublet of reduced electrophoretic mobility, a doublet that 
would correspond to the addition of a 30 kDa E G F P to MRP1. No proteolysis products 
were recognized by either antibody, c-d. MRP1-EGFP transfected cells were probed with 
an anti-MRP1 antibody and examined under confocal microscopy to determine the extent 
of co-localization between the E G F P (c) and anti-MRP1 (d) fluorescent signals. E G F P 
fluorescence was merged with the fluorescence derived from labeled M R P 1 (e) to 
demonstrate the extent of the colocalization. f. The relative fluorescence intensities of 
both labels were plotted in a line scan of the merged image. The scale bar for the 
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Figure 3-4 MRP1-ECFP is active against the M D R substrate T M R E . 
a-c. MRP1-ECFP transfected HeLa cells were assayed for protein transport activity with 
T M R E , a live-stain dye which is also a known M R P 1 substrate. The cell positive for 
MRP1-ECFP expression (a) showed reduced T M R E accumulation (b-c) compared to its 
non-MRP1-ECFP expressing counterparts (b-c). d-e. To determine whether the 
reduction in T M R E accumulation was as a result of loss of cell viability or active, MRP1-
mediated transport, cells were treated with the M R P 1 inhibitor verapamil prior to the 
T M R E assay. MRP1-ECFP expressing cells (d) now accumulated T M R E (e-f), 
suggesting that MRP1-ECFP was capable of active transport. 
M R P 1 - E G F P Daunorubicin M e r g e 
M R P 1 - E G F P Doxorubicin M e r g e 
M R P 1 - E G F P Mitoxantrone M e r g e 
- i m m **-̂  
Figure 3-5 M R P 1 - E G F P has activity against weakly basic chemotherapeutic 
agents. HeLa cells were transiently transfected with MRP1-EGFP and observed 48 
hours after transfection for the accumulation of fluorescent chemotherapeutic drugs. 
Cells incubated in 10 m M daunorubicin (a-c) showed nuclear and preinuclear 
accumulation of the drug after 15 minutes (b); however, expression of MRP1-GFP (a) 
substantially diminished the intracellular accumulation of daunorubicin, a pattern 
made evident in the merged image (c). W h e n transiently transfected HeLa cells were 
incubated in doxorubicin (d-e), the expression of M R P 1 (d) was able to alter the 
intracellular distribution of the drug so that it was no longer present in the nucleus (e). 
The merged image (f) makes this pattern clear. Finally, cells were incubated in 2 m M 
mitoxantrone and observed for MRP1-mediated changes in drug accumulation (g-i). 
M R P 1 expression (g) resulted in a slight decrease in mitoxantrone accumulation (h), 
an observation made clear in the merged image (i). 
Figure 3-6 F A C S analysis of MRP1-EGFP activity. 
a. The expression of MRP1-EGFP substantially diminished the intracellular accumulation of 
daunorubicin, a reduction that was greater than 10 fold when E G F P fluorescence was 100 
fold over background, b. FACS was also performed of daunorubicin accumulation in Pgp-
G F P transfected cells for comparison, c. When transiently transfected HeLa cells were 
incubated in doxorubicin, no change in the total intracellular accumulation of the drug was 
observed under FACS for MRP1-GFP expressing cells over the entire range of E G F P 
fluorescence, d. A FACS analysis of Pgp-EGFP expressing cells incubated in doxorubicin 
was conducted for comparison, e. Cells were incubated in 2 nM mitoxantrone and 
observed for MRP1-mediated changes in drug accumulation. M R P 1 expression only 
resulted in a slight decrease in mitoxantrone accumulation in cells with the greatest EGFP 
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Figure 3-7 Methods of visualizing the microtubule cytoskeleton. 
a. Hela cells were transfected with tau-ECFP and examined 24-48 h. later for 
microtubule structure, b. HeLa cells were fixed and probed with a Cy3-labeled anti-B 
tubulin antibody and then examined for microtubule structure. 
Figure 3-8 Assaying M R P 1 transport of mictotubule depolymerizing agents. 
HeLa cells were separately transfected with MRP1-EYFP or Pgp-ECFP; cells were 
plated together, and incubated in a microtubule-disrupting agent, and examined for the 
extent of microtubule damage with a fluorescent anti-tubulin antibody, a-e. An 
incubation in 600 nM vincristine resulted in substantial microtubule disruption in cells 
that did not express either M D R protein (c). Cells expressing MRP1-EYFP (a) were 
afforded some chemo-protection against vincristine-mediated cytotoxicity (c, e), and 
cells with Pgp-ECFP (b) were relatively unaffected (c, d). f-j. Cells incubated in 2 m M 
colchicine were examined for microtubule damage. MRP1-EYFP expressing cells (f), 
as well as Pgp-ECFP expressing cells (g), maintained a complex microtubule structure 
in the presence of colchicine (i), while non-expressing had almost completely 
depolymerized microtubules (h,i,j). k-o. Incubating cells in 600nM vinblastine 
resulted in almost complete depolymerization of both MRP1-EYFP expressing cells (k, 
o) and non-expressing cells (m, n, o), whereas cells expressing Pgp-ECFP (I) were 
much less affected by the drug (m-o). 
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4 Chapter 4 Localization of MRP1 
In the previous chapter, we demonstrated that the MRP 1-EGFP fusion 
protein is functional, localizes to the plasma membrane, and has an activity profile 
analogous to wild-type MRP1. We also saw that a fraction of the total MRP1 
pool localized to a region within the cell and adjacent to the nucleus, and another 
fraction to the plasma membrane. We next wanted to examine the sub-cellular 
distribution of MRP 1, within two particular contexts. First, we wanted to 
determine whether MRP 1-ECFP would undergo polarization-dependent sorting to 
the plasma membrane in cells capable of polarization. Second, we wanted to 
identify the sub-cellular organelles within which MRP1 might be found. Given 
the fluorescent nature of the MRP1-ECFP construct, live cell-examinations of 
MRP1 localization would be possible using fluorescence microscopy in 
conjunction with live-cell fluorescent markers for sub-cellular organelles. Several 
such markers are commercially available and include reporters for the ER, the 
Golgi, the recycling endosomes, and the lysosomes. Considering the peri-nuclear 
localization of MRP 1, these particular markers would be helpful in determining 
the organelle or organelles in which MRP1 might be found. 
4.1 Expression in Polarized Cells 
To determine whether MRP 1-ECFP would be expressed in a polarized 
fashion in epithelial cells, polarized MDCK cells were transfected with MRP1-
ECFP and visualized 24 hours later, using deconvolution microscopy. This 
technique collects light from multiple sections of a sample at specified distances 
in the Z plane, in our case every 1.5 um, and using a nearest neighbor 
deconvolution algorithm, reallocates out of plane fluorescence. Deconvolution 
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microscopy thereby allows for a more direct sampling of cell sections, 
and minimizes the contribution of fluorescent signals from other focal planes. 
When MRP 1-ECFP transfected MDCK cells were examined in this fashion, 
MRP 1-ECFP was found at the basal membrane (Fig. 4-1 a) and at the lateral 
membrane (Fig. 4-1 b), but the protein was not present at the apical surface (Fig. 
4-1 c). This distribution is in contrast to the localization of MRP 1-ECFP in non-
polarized cells. HeLa cells, for example, express the protein at the basal surface 
(Fig. 4-1 d), the lateral surface (Fig. 4-1 e, arrow), as well as the apical surface 
(Fig. 4-1 f)- Baso-lateral localization for wild-type MRP1 has been previously 
reported (Evers et al, 1996). 
4.2 Perinuclear localization of MRP1-ECFP in multiple cell lines 
In Hela cells, MRP 1-ECFP fluorescence was evident adjacent to the 
nucleus. To ensure that this localization pattern was not specific to one cell type, 
a number of other cell types were transfected with MRP 1-ECFP and examined 
under wide-field epi-fluorescence microscopy for the sub-cellular distribution of 
the protein. In the mouse embryonic stem cell line BDC1, for example, 
fluorescence from MRP 1-ECFP was present in a region surrounding the nucleus 
(Fig. 4-2 a, arrow), as well as at the plasma membrane. In this micrograph, the 
rim-staining that generally characterizes plasma membrane-localized markers was 
less visible. However, the apparent sub-cellular distribution of MRP 1-ECFP was 
highly dependent upon the focal plane visualized for all the cells and cell types 
used in this study. Depending upon the cell and the focal plane chosen, MRP1-
ECFP was more or less evident at the plasma membrane or the peri-nuclear region 
for BDC1 cells (Fig. 4-2 a), for the immortalized mouse line NIH 3T3 (Fig. 4-2 
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b), for the primary human fibroblast NHDF (Fig. 4-2 c), and for the 
glutathione mutant mouse embryonic stem cell line GCS2-NAC (Fig. 4-2 d). 
Hence, while peri-nuclear staining was clear in the micrograph of the NHDF cell 
(Fig. 4-2 c), rim-staining was less evident. In the same fashion, the rim-staining 
of the NIH 3T3 cell was clear, while the peri-nuclear staining was not (Fig. 4-2 b). 
In some cases, the relative distribution of the organelles in a cell made a rim-stain 
and a peri-nuclear stain both evident (Fig. 4-2 d). Nevertheless, in all cells 
examined for the sub-cellular distribution of MRP1-ECFP, the protein was found 
both at the plasma membrane and in a peri-nuclear compartment. 
4.3 Characterizing the sub-cellular distribution of MRP1 
Since a significant fraction of the total MRP1 expressed in a cell localized 
to an intracellular compartment, we next wanted to determine which organelle or 
organelles were constituents of this compartment. To establish whether MRP1 
resided in a particular organelle, we used fluorescent markers for organelles found 
in the peri-nuclear region of the cell, and we determined the degree of spatial 
correlation between the fluorescent signal of the marker and the fluorescent signal 
of MRPL We began our search with fluorescent reporters for the Golgi and the 
recycling endosomes. For in vivo labeling of the Golgi, we used a fluorescently-
tagged, truncated version of human Golgi resident protein beta 1,4-galactosyl-
transferase, a commercially available reporter (Clontech) shown to be a specific 
marker for the trans Golgi compartment (Llopis et al, 1998). For the recycling 
endosomes, we used cy-3 labeled transferrin, a protein which binds the transferrin 
receptor and is in this way interalized by the cell to label the recycling 
endosomes (Lampson et al, 2001). 
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HeLa cells were transfected with both MRP 1-ECFP and Golgi-
EYFP and then loaded with cy3-labeled transferrin. When cells were next 
visualized using epi-fluorescent microscopy, we found that all three fluorescent 
labels accumulated in a peri-nuclear region (Fig. 4-3, a-d). We could not easily 
distinguish the degree to which MRP 1-ECFP signal derived from the Golgi or the 
recycling endosomes, as the markers themselves overlapped. Moreover, because 
the images represented light collected from the entire sample, we were not able to 
distinguish localization patterns in the Z plane. In an attempt to spatially 
segregate these markers, we treated cells with BFA, a reagent which induces 
retrograde transport from the Golgi to the ER, and thus has the effect of 
collapsing the Golgi apparatus back into the ER (Lippincott-Schwartz et al, 
1990). If the MRP 1-ECFP signal emanated from the recycling endosomes, it 
would not be affected by the addition of BFA. However, if peri-nuclear MRP1-
ECFP resided primarily in the Golgi, we would expect to see a more reticulate 
distribution for the transporter upon BFA addition. When we added BFA to these 
cells, we were not able to make a reliable assessment of the effect of BFA on 
MRP1 localization, even after comparing cells in the same field before and after 
the addition of the drug (Fig. 4-3, a-d vs. e-h). Cell movements between these 
two visualization times made comparisons of cells pre-and-post BFA treatment 
difficult, as we could not account for the changes in organellar distribution caused 
by cell movement. Moreover, the addition of BFA did not completely collapse 
the Golgi into the ER in every cell, and therefore the problem of overlapping 
signals in the Z plane was not resolved. 
In order to improve our resolution in the Z plane, and thereby distinguish 
over-lapping markers in the peri-nuclear region, we decided to use deconvolution 
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microscopy once again. HeLa cells transfected with MRP 1-ECFP were 
incubated in cy3-transferrin to label the recycling endosomal compartment and 
then sections of cells were examined for co-localization of the two markers. 
Deconvolution microscopy enabled us to visualize individual MRP 1-ECFP 
vesicles in the peri-nuclear region (Fig. 4-4 a), as well as individual vesicles of the 
endosomal compartment (Fig. 4-4, b). The merge of these two fluorescent signals 
(Fig. 4-4 c), as well as an enlarged image of the peri-nuclear region (Fig. 4-4 d-f) 
demonstrated that very little of the MRP 1-ECFP signal emanated from the 
recycling endosomes. Vesicles contained either MRP 1-ECFP or cy3-transferrin. 
Few, if any, contained both. 
We decided next to determine whether MRP1 might reside in the Golgi, 
by transfecting cells with MRP 1-ECFP and Golgi-EYFP, and once again 
examining cells using deconvolution microscopy. Individual cell sections 
revealed vesicles labeled with either MRP 1-ECFP (Fig. 4-5, a,d) or Golgi-EFYP 
(Fig. 4-5, b,e), but rarely were there ever vesicles that expressed both fluorescent 
markers together (Fig. 4-5, c, f). Similar results were obtained when cells were 
transfected with MRP 1-ECFP and a fluorescent marker for the ER (Fig. 4-5, g-1). 
Both MRP 1-ECFP and ER-EYFP were found in peri-nuclear vesicles, but there 
was very little co-localization of these markers in these vesicles. 
MRP 1-ECFP might also reside in the lysosomes. ABC proteins are 
known to be expressed in the vacuole of non-mammalian systems (Li et al, 
1996;Lu et al, 1997), and in mammals, proteins that are not part of the ABC 
family do confer drug resistance from lysosomes (Cabrita et al, 1999). 
Moreover, lysosomes may promote drug detoxification and in this way provide a 
link between two distinct multidrug resistance pathways. We decided to test this 
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possibility by chasing fluorescently-labeled dextrans into the lysosomes 
of MRP 1-ECFP transfected cells. Fluorescent dextrans are routinely employed to 
label the different stages of the endocytic pathway of living cells. When 
incubated in fluorescent dextrans, cells will endocytose these particles, and 
depending upon the length of the chase, the dextrans will reside in the early or late 
endosomes, or if given enough time, in the lysosomal compartment. The 
lysosomes of MRP 1-ECFP transfected HeLa cells were labeled in this fashion, 
and then examined for the degree to which the ECFP signal emanated from 
regions of the cell that were positive for Texas-Red dextrans. Once again, MRP1-
ECFP fluorescence was evident at the plasma membrane and in a peri-nuclear 
compartment (Fig. 4-6, a, d). Fluorescence from lysosomes (Fig. 4-6, b,e) 
correlated spatially with that from MRP 1-ECFP (compare Fig. 4-6, d, with Fig. 5-
6, e), and these two signals appeared to emanate from the same vesicles. To 
verify these results with another marker for the lysosomes, we chose to co-express 
MRP1 with synaptotagmin VII, a lysosomal membrane protein that is also found 
in some cell types at the plasma membrane. When Hela cells were co-transfected 
with MRP1-EYFP and synaptotagmin VII-ECFP, we found that these cells had 
vesicles positive for both fluorescent proteins (Fig. 4-7, vesicles of note are 
circled for ease of identification). 
These co-localization studies suggested that MRP 1-ECFP resides in the 
lysosomes during some time in its trafficking history. As plasma membrane 
proteins are routed to the lysosomal compartment for degradation, we became 
concerned that the MRP1-ECFP present in this compartment may represent an 
aberrant localization pattern, one introduced solely by the ECFP tag, perhaps as a 
result of a protein misfolding event that targeted MRP 1-ECFP for proteolysis. 
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However, if the peri-nuclear fluorescence represented degraded protein, 
it should have been detectable by Western blot, as intracellular MRP 1 constituted 
a considerable fraction of the total protein expressed. Our previous 
investigations of MRP 1-EGFP expression indicated that the large fraction of 
MRP1-EGFP being expressed by the cell was not proteolyzed (Chapter 3). On 
the other hand, it is possible that the lysosomal localization of the protein was an 
artifact of the ECFP tag, effecting the trafficking dynamics of the protein in way 
that misrepresented the localization of wild-type MRPL To determine if the 
fluorescent tag was responsible for aberrant localization of MRP 1, synaptotagmin 
VII was transfected into HeLa cells along with wild-type MRP1, and 
immunocytochemistry was performed using the MRP 1 antibody MRPrl. We 
found that wild-type MRP1 co-localized with synaptotagmin VII in a region 
adjacent to the nucleus (Fig. 4-8, a-c). Under deconvolution microscopy, we 
could distinguish vesicles which contained both MRP1 (Fig. 4-8, d, f circles) and 
synaptotagmin VII (Fig. 4-8, e-f circles). As an added assurance, we wanted to 
determine whether MRP1 would co-localize with another lysosomal marker. As 
our fluorescent dextrans would not withstand the fixation process, we chose 
another lysosomal resident protein for our studies, cathepsin D. In accordance 
with our previous findings, wild-type MRP1 was found to co-localize with this 
lysosomal marker as well (Fig. 4-9). 
We next wanted to determine whether this lysosomal localization pattern 
of MRP 1 would be exhibited by other ABC proteins, particularly those involved 
in conferring drug resistance. We therefore transfected HeLa cells with 
fluorescent conjugates of other MDR proteins, in particular, Pgp and BCRP, both 
of which have been implicated in the acquisition of drug resistance in a clinical 
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setting. As with MRP1, we used fluorescent conjugates of Pgp and 
BCRP to examine the sub-cellular localization of these proteins. Both fluorescent 
proteins have been examined in detail and have been found to be reliable markers 
of wild-type Pgp and BCRP. Neither fluorescent conjugate is subject to extensive 
proteolysis, as determined by Western Blot, and both proteins reduce the 
intracellular accumulation of chemotherapeutic agents (Kartner et al, 1983). 
When the lysosomes of Pgp-ECFP transfected HeLa cells were labeled with 
fluorescent dextrans, we found that both fluorescent signals emanated from the 
peri-nuclear region of the cell. Moreover, individual vesicles that contained both 
Pgp and the lysosomal marker were easily detected (Fig. 4-10, circles). In the 
same fashion, we found BCRP-ECFP also to localize to lysosomal vesicles within 
the perinuclear region of HeLa cells (Fig. 4-11). 
However, when we examined an ABC protein not implicated in the 
acquisition of multi-drug resistance, we found that the protein did not localize to 
the lysosomes. CFTR, like MRP1, Pgp, and BCRP, was studied as a protein 
conjugate of ECFP, and its subcellular distribution was determined by employing 
fluorescent dextrans chased into the lysosomes. The intracellular localization of 
CFTR varied from cell to cell in each round of transfection, from a primarily 
reticulate, intracellular distribution (Fig. 4-12, a) that most resembled the 
distribution of an ER protein (Fig. 4-12, g), to a primarily plasma membrane-
localized protein (Fig. 4-12, b). However, at no point did CFTR-ECFP co-
localize with lysosomal dextrans (Fig. 4-12, b, e), as evident in the merge of the 
two fluorescent signals (Fig. 4-12, c, f). This data is suggestive of a functional 
relationship between drug resistance proteins and lysosomal targeting, a pattern 
that we will discuss further in the next chapter. 
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4.4 Quantifying co-localization 
Thus far, determinations of co-localization had been performed entirely by 
visual inspection. We now wanted to quantify the degree to which MRP1, or any 
other fluorescent ABC protein, could be said to reside in one organelle, or another, 
and thereby remove the arbitrary nature of visual assessments. Moreover, 
quantification of visual data would enable us to compare the results of different 
experiments and enable us to assess relative degrees of correlation between 
different fluorescent markers. In order to do this, we used a correlation algorithm 
available to us from MetaMorph software. For a given micrograph, this algorithm 
determines the degree to which distinct fluorophores vary their intensities through a 
two-dimensional space in a coordinated fashion, and represents this information in a 
"correlation coefficient." Correlation coefficients are expressed on a scale of-1 to 
1, with -1 representing no correlation whatsoever, and 1 representing identity. To 
better understand the nature of this quantification, we wanted to test the scaling 
system by acquiring correlation coefficients for either end of the spectrum: for 
proteins that should co-localize entirely and therefore represent identity, and for 
proteins that should share very little in their sub-cellular distribution. 
To test the former, we began by transfecting cells with two versions of the 
same protein, MRP1-EYFP and MRP 1-ECFP. Differing only in their fluorescent 
tags, these proteins should share similar localization patterns and set the upper limit 
of co-localization. When HeLa cells were co-transfected with MRP1-EYFP and 
MRP 1-ECFP, we found that the two proteins did share very similar distributions; 
again both were targeted to the plasma membrane and a peri-nuclear region (Fig. 4-
13 a-c). Closer inspection of the peri-nuclear region revealed individual vesicles 
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that shared the two fluorophores (Fig. 4-13, d, e; for example, circle 1). 
However, there were also a number of vesicles that contained predominantly one 
fluorophore over another (Fig. 4-13, d,e; for example, circle 2). Indeed, there were 
surprising differences in the vesicular distribution of these two proteins, differences 
which would made a correlation co-efficient of 1 less likely (Fig. 4-13, d,e, other 
circles). When these images were analyzed for correlation coefficients, we found 
an average assignment of 0.7677 for MRP1-EYFP and MRP 1-ECFP. 
To find the lower limit of co-localization, we chose to examine Golgi-EYFP 
transfected cells whose recycling endosomes were labeled with cy-3 transferrin 
(Fig. 4-13, f-h). The correlation coefficient for this pair was 0.2699, suggesting that 
even distinct organelles are characterized by overlapping pixels. This correlation 
co-efficient may represent patterns of vesicular exchange between the organelles, or 
it may be an artifact of pixel density and distribution in the confined space of a cell. 
Nevertheless, we allowed this correlation co-efficient, along with that found for the 
doubly transfected MRP1 expressing cells, to define the limits of our quantification. 
With these limits in mind, we then generated correlation co-efficients for the 
micrographs analyzed thus far for co-localization, and plotted them on a line graph 
(Fig. 4-14, a-c). These numerical assessments of co-localization supported our 
previous understanding of MRP 1 localization. MRP1, like MRP 1-ECFP, localizes 
primarily to the lysosomal compartment 24-48 hours after transfection (Fig. 4-14 
a,b). Very little of the protein is found in the ER, the recycling endosomes, or the 
Golgi (Fig. 4-14, a). Analysis of the localization of Pgp-ECFP and BCRP-ECFP 
suggest a similar pattern; both proteins can be found primarily in the lysosomal 
compartment 48 hours after transfection, while CFTR-ECFP, a non-MDR ABC 
protein, is not to be found there (Fig. 4-14, c). 
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The demonstration of a lysosomal distribution for MRP1, Pgp, and 
BCRP, does not preclude sub-cellular localization elsewhere. Indeed, this 
intracellular distribution may be a factor of cell cycle or trafficking history, and 
these proteins may present themselves in other locations under different conditions, 
or at different times. MRP2, for example, has been found in a novel subcellular 
organelle in nonpolarized hepatic cells (Tuma et al, 2002). However, it would not 
be unprecedented to propose that MRP1, BCRP, and Pgp all reside in the 
lysosomes. ABC proteins are known to be expressed in the vacuole of non-
mammalian systems (Li et al, 1996;Lu et al, 1997), and in mammals, proteins that 
are not part of the ABC family do confer drug resistance from lysosomes (Cabrita et 
al, 1999). Moreover, lysosomes may promote the detoxification of the drug and in 
this way provide a link between two distinct multidrug resistance pathways. 
Whether this sub-cellular localization pattern of these MDR transporters is a result 
of over-expression is not known. In so far as multidrug resistant cancer cells are 
known to over-express ABC transporters like MRP1, the over-expression system 
used in this study models itself after a patho-physiological state. However, 
predominantly intracellular localization patterns for MRP1 have been reported for 
many normal tissues (Flens et al, 1996;Wioland et al, 2000). Moreover, we found 
that cells expressing even low levels of MRP1-CFP were characterized by primarily 
intracellular versions of the protein, suggesting that vesicular MRP1 may not be the 
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Figure 4-1 MRP1-ECFP is sorted to the baso-lateral membrane. 
a-c. MRP1-ECFP was transfected into M D C K epithelial cells after 
polarization and examined 24-48 hours later. MRP1-ECFP was observed 
at the basal surface and the lateral surface, but not the apical surface in 
these cells, d-f. Non-polarized cells transfected with MRP1-ECFP 
expressed the protein at the plasma membrane. Arrows indicate lateral 
surface. 
B D C 1 N I H 3 T 3 
g B ^ < j l U I H I 1 ^ 1 
N H D F G C S 2 - N A C 
Figure 4-2 MRP1-ECFP localization in four cell types. MRP1-ECFP localizes 
to the plasma membrane and, to varying degrees, a peri-nuclear region, as seen 
in four different cell types. Cell types are as follows: a. a mouse embryonic cell 
line; b. an immortalized mouse cell line; c. a primary, human fibroblast line; and d. 
a mouse embryonic cell line incapable of glutathione production. Arrows indicate 
the peri-nuclear region. 
Figure 4-3 Localizing organelles with epi-fluorescent microscopy a-d. Hela 
cells transfected with MRP1-ECFP and Golgi-EYFP were labeled with Cy3-Tfn to 
visualize recycling endosomes. Cells showed a perinuclear staining for all three 
fluorescent signals, making sub-cellular determinations of MRP1-ECFP localization 
difficult, e-h. The addition of BFA did not clarify MRP1-ECFP distribution patterns, 
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Figure 4-4 MRP1-ECFP does not localize to the recycling endosomes. 
a-c. MRP1-ECFP transfected cells were loaded with cy3-transferrin and examined with 
a deconvolution fluorescent microscope to determine the degree to which the M R P 1 -
E C F P signal (a) co-localized with the recycling endosomes (b). One section of the cell 
is presented, d-e. An enlarged image of the cell depicted in (a-c) makes evident the 
degree to which MRP1-ECFP does not co-localize with the recycling endosomal 
compartment. The vesicles containing each fluorescent signal are distinct. 
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Figure 4-5 MRP1-ECFP does not localize to the Gogli or the E R 
a-c. Hela cells were transfected with both MRP1-ECFP (a) and Golgi-EYFP (b), 
and examined with a deconvolution fluorescent microscope to determine the 
extent of the colocaliztation. d-e. An enlarged image of the cell above in which 
vesicles containing one or the other of the two fluorescent markers are clear, g-l. 
Hela cells were transfected with MRP1-ECFP (g, j) and ER-EYFP (h, k) to 
determine the extent of the co-localization. Few vesicles, if any, were 
simultaneously labeled with two fluorescent signals. 
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Figure 4-6 MRP1-ECFP co-localizes with a lysosomal marker 
a-c. MRP1-ECFP transfected Hela cells were incubated with fluorescent 
dextrans that were chased into the lysosomes. The MRP1-ECFP signal (a, d) 
correlated with that of the lysosomal marker (b, e), as seen in the merged image 
(c, f). Three second time delays occurred between image acquisitions, during 
which time, vesicular movement precluded absolute spatial resolution of the two 
fluorophores. 
Figure 4-7 MRP1-EYFP co-localizes with synaptotagmin VII 
a-c. Hela cells were transfected with MRP1-EYFP (a) and synaptotagmin VII (b), a 
lysosomal membrane marker, and then were imaged using deconvolution microscopy. 
A section of a cell is presented in which some of the vesicles that clearly express both 
proteins are circled. 
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Figure 4-8 Wild type M R P 1 co-localizes with synaptotagmin VII 
a-c. HeLa cells were transfected with M R P 1 and synaptotagmin VII (a) and then probed 
with the anti-MRP1 antibody MRPrl for the presence of wild type M R P 1 (b) in 
lysosomes. d-f. An enlarged section of a cell co-transfected with wild-type M R P 1 and 
synaptotagmin VII. Circles indicate vesicles that are positive for both proteins. 
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Figure 4-9 Wild-type M R P 1 co-localizes with the lysosomal marker 
cathepsin D 
a-c. M R P 1 transfected HeLa cells were fixed and probed for wild-type 
M R P 1 (a) as well as the lysosomal resident protein cathepsin D (b). 
Once cell section is represented, d-f. An enlarged image of another 
section of the same cell presented in a-c. 
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Figure 4-10 Pgp-ECFP can also be found in vesicles positive for a 
lysosomal marker 
a-c. A HeLa cell was transfected with Pgp-ECFP (a) and then labeled with 
fluorescent dextrans chased into the lysosomes (b). Circles call attention to 
vesicles containing both fluorescent signals. 
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Figure 4-11 BCRP-ECFP is found in lysosomes 
a-c BCRP-ECFP transfected cells were loaded with fluorescent dextrans to label the 
lysosomes. BCRP-ECFP (a) was found in vesicles in the peri-nuclear region of cells, 
and these vesicles were positive for fluorescent dextrans (b), as seen in the merge (c). 
d-f. An enlarged region of a BCFP-ECFP transfected cell in which vesicles positive for 
B C R P (d) and fluorescent dextrans (e) are apparent (circles, f) 
C F T R - E C F P T X - R e d Dextran M e r g e 
Figure 4-12 CFTR-ECFP is not found in lysosomes. 
a-f. The lysosomes of HeLa cells transfected with CFTR-ECFP (a, d) were labeled with 
fluorescent dextrans to determine whether C F T R could be found in the lysosomes. g. 
A HeLa cell transfected with ER-EYFP is shown as a point of comparison. 
M R P 1 - E Y F P M R P 1 - E C F P m e r g e 
Figure 4-13 Determining the limits of co-localization. 
a-c. HeLa cells were transfected with MRP1-EYFP and MRP1-ECFP to determine 
the extent of the co-localization of the two markers, d-e. An enlarged image of the 
cell presented in a-e, in which vesicles containing the two fluorophores are visible. 
Circles indicate variability in co-localization in a positive control, f-h. The Golgi 
apparatus and the recycling endosomal compartment were labeled in HeLa cells to 




0>£ « C I, 
C « *? re** l̂  
.- o o ™<0 >-
u ft .— "• Xq_t-
fro » 2 -gc"Q-
Sj £§ 8, sr si 
M R P I - E C F P a n d • • • . • subcellular markers 
b 
Wildtype M R P 1 and 
re c rac 
Other A B C proteins 










-1 1 •—1 1 •-
subcellular markers °-° 0.2 0.4 0.6 0.8 1.0 
C <A C (/> -r,</> 
C 
^ 2 q-2 « 5 
LL (j) KJ Qi O)0) 
OTJ CQTS 0.TJ 
I # I 1 •"! 1 • 1 
0.0 0.2 0.4 0.6 0.8 1.0 
Figure 4-14 Correlation Coefficients permit quantification of protein co-
localization studies, a. Correlation coefficients for MRP1-ECFP and various 
subcellular markers are plotted. Correlation coefficients for wild-type M R P 1 and 
the lysosomal compartment are plotted, c. Correlation coefficients for other 
A B C proteins and the lysosomal compartment are plotted. 
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5 Chapter 5 Subcellular activity of MRP1 
5.1 Drug sequestration 
In the last chapter, we determined that MRP1 localizes both to the plasma 
membrane and to an intracellular compartment that is positive for at least three 
different lysosomal markers. We found that this distribution pattern characterized 
the expression of MRP 1-ECFP, as well as the expression of wild-type MRPL 
We also discovered that this subcellular localization pattern was shared by other 
MDR-conferring proteins, transporters like P-glycoprotein and BCRP, but not by 
other ABC proteins, like CFTR. We now wanted to determine whether this 
intracellular distribution was of any physiological relevance to the cell. In 
particular, we wondered whether these MDR proteins could be active in these 
compartments, and whether this activity could contribute to drug resistance. 
There is some precedence for suggesting that these proteins might be 
functional within sub-cellular compartments. Non-mammalian members of the 
ABC family, for example, are known to be active in intracellular compartments. 
The yeast cadmium factor 1 (YCF1) and plant homologues of the human MRP1, 
Arabidopsis thaliana MRP1 and MRP2, are all thought to transport substances 
from the vacuolar membrane into the vacuole (Li et al, 1996;Lu et al, 1997;Lu et 
al, 1998). As the storage compartment for toxins of varied sources, the vacuole 
serves in a drug resistance capacity, sequestering everything from herbicides and 
anti-microbial agents to oxidizing metabolites from the rest of the cell. In a 
similar fashion, the lysosomal compartment, where we have found human MRP1 
to reside, has been implicated in an analogous role: providing drug resistance by 
sequestering toxins away from the rest of the cell (Hurwitz et al, 1997). The 
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MCF7-Adr cell line, for example, is a multidrug resistant line whose 
drug resistance is in main part due to the sequestration of drug away from the 
nucleus in lysosomes, as well as other intracellular organelles (Altan et al, 1998) 
(Fig. 5-1, a). In contrast, the parental line, MCF7, is sensitive to chemotherpeutic 
agents like doxorubicin which accumulates in the nucleus, the site of doxorubicin 
toxicity (Fig. 5-1, b). 
Drug sequestration is a well-characterized mechanism of conferring drug 
resistance, and it is thought to be mediated by altered intracellular pH. Drug 
resistant cells frequently have intracellular compartments that are acidified and 
therefore more likely to accumulate weakly basic drugs like doxorubicin. 
Disrupting cellular acidification with the addition of concanamycin A, for 
example, results in the redistribution of chemotherapeutics into the nucleus of 
some drug resistant cell lines like MCF7-Adr (Fig. 5-1, c) (Altan et al, 1998). 
However, it is possible that other drug sequestration mechanisms are at work here. 
MCF7-Adr cells are known to express both MRP1 (see the following chapter) and 
Pgp. Inhibiting the activity of these two proteins with verapamil redistributes 
doxorubicin away from sub-cellular compartments and into the nucleus (Fig. 5-1, 
d), suggesting a role for one or both of these proteins in altering drug distribution. 
Moreover, doxorubicin in these cells is sequestered in the lysosomes, and may 
suggest that lysosomally-localized MRP1 and Pgp are both active and contribute 
to drug sequestration (Fig. 5-l,e). Finally, the expression of MRP 1 in the MCF7 
sensitive line is sufficient to redistribute the drug away from the nucleus into sub-
cellular organelles (Fig. 5-2, a-f), in pH independent manner (Fig. 5-2, d-f), much 
like MCF7-Adr cells. 
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For all of these reasons, we wanted to determine whether MRP1 
retained transport activity within sub-cellular organelles. In order to investigate 
this question, we asked the following questions: one, are drug substrates found to 
co-localize with MRP 1-containing organelles; two, is this co-localization 
reversible upon the inhibition of MRP 1 activity; three, is drug accumulation into 
MRP1 organelles affected by alterations in organellar pH; and four, if the activity 
of cell surface MRP1 is blocked, will drug accumulation in MRP 1-positive 
organelles still occur? In this fashion, we would test if patterns of intracellular 
drug accumulation correlated with intracellular MRP1 activity, and not with other 
cellular phenomena frequently associated with drug resistance. 
5.2 Doxorubicin localizes to MRP1-ECFP containing vesicles 
We first compared the drug accumulation patterns of cells transfected with 
MRP 1-ECFP to those expressing only endogenous MRP1 (Fig. 5-3). We found 
that HeLa cells with only endogenous MRP1 accumulated doxorubicin in the 
nucleus, and to a lesser extent, in vesicle-like structures around the nucleus (Fig. 
5-3, a-c). For the most part, these structures did not co-localize with a marker for 
the lysosomes (Fig. 5-3, d-f); however, this conclusion is suggested only by epi-
fluorescence microscopy, and extensive studies have not been conducted 
regarding this question using either confocal or deconvolution microscopy. 
However, the expression of MRP 1-ECFP in HeLa cells resulted in a dramatic 
redistribution of doxorubicin fluorescence, with almost no visible fluorescence 
emanating from the nucleus, and an enriched accumulation of the drug in a peri-
nuclear region (Fig. 5-3, h) that co-localizes with peri-nuclear MRP1 (Fig. 5-3, g, 
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To determine whether doxorubicin in this peri-nuclear 
compartment was indeed accumulating in MRP 1-containing organelles, we 
examined the localization of both using deconvolution microscopy. We found 
that the peri-nuclear region positive for both doxorubicin and MRP 1-ECFP (Fig. 
5-4, a-c) was composed of what looked liked individual vesicles containing both 
fluorophores (Fig. 5-4, d-f). In this case, the merge of the two images (Fig. 5-4, f) 
did not always result in yellow where the vesicles co-localized. Because these 
images represent living cells with rapidly moving vesicles, one second time 
delays between the acquisition of the images sometimes precluded absolute 
spatial co-localization. Additionally, the relative intensities of the two 
fluorophores are not matched, and vesicles labeled with more of one reporter than 
another do not appear yellow. 
Infrequently, MRP 1-ECFP was localized anomalously in HeLa cells; that 
is, it was found in regions other than the plasma membrane and the perinuclear 
region. This observation was not unexpected, as Hela cells are not clonal, but a 
genotypically heterogeneous, transformed cell line. In an extremely rare instance, 
for example, MRP 1-ECFP accumulated in what appeared to be large aggregates 
within the endo-membrane system (Fig. 5-4, g). Surprisingly, in this same multi-
nucleated MRP 1-ECFP expressing cell, doxorubicin was also found distributed 
throughout the endo-membrane system (Fig. 5-4, h) in a pattern very similar to 
the distribution of MRP 1-ECFP (Fig. 5-4, i). Doxorubicin only assumed this 
dispersed sub-cellular distribution when MRP 1-ECFP was likewise dispersed, and 
never in a cell that was not transfected with an MDR protein. Despite this 
anomalous localization pattern for MRP1, the protein was still active in the cell, 
and the expression of MRP 1-ECFP still resulted in the exclusion of the drug from 
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the nucleus (Fig. 5-4, h). The observation that the intracellular 
distribution of doxorubicin varies with the intracellular distribution of MRP1-
ECFP is suggestive that the protein has sub-cellular activity. 
Moreover, in instances when the MRP 1-ECFP plasmid was poorly 
expressed in HeLa cells, the protein was found only in intracellular 
compartments, and not at the plasma membrane at all (Fig. 5-4, j). This result 
suggests that the intracellular localization of the protein is not an artifact of an 
over-expression system. However, despite weak expression of this protein, cells 
like this one still accumulated the drug in MRP 1-ECFP expressing vesicles, even 
if expression of the protein was not sufficient to exclude the drug from the 
nucleus (Fig. 5-4, k-1). 
Therefore, in addition to the plasma membrane, MRP 1-ECFP localized to 
intracellular compartments that were peripheral to the nucleus. Within these 
vesicles, MRP 1-ECFP fluorescence was coincident with doxorubicin 
fluorescence, a finding which would be consistent with MRP 1-mediated 
sequestration of the drug away from the nucleus. In rare instances, when a cell 
exhibited an altered pattern of intracellular MRP1 distribution, doxorubicin also 
assumed this altered pattern, arguing strongly that intracellular MRP 1 actively 
transports doxorubicin. 
5.3 Doxorubicin sequestration in MRPl-vesicles is dependent on MRP1 
activity 
We next wanted to determine if doxorubicin accumulation in MRP1-
containing vesicles was dependent upon MRP1 activity, or simply a result of 
altered pH in MRPl-vesicles. If intracellular MRP1 is to be found predominantly 
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in the lysosomal compartment, then the lysosomal accumulation of a 
weakly basic chemotherapeutic like doxorubicin could simply be a function of 
acidification in these compartments. We therefore assayed the effect of 
concanamycin A on the sub-cellular distribution of doxorubicin in MRP 1-ECFP 
expressing cells. Concanamycin A inhibits organellar acidification, as assayed by 
the pH sensitive dye acridine orange, which fluoresces in the red in a low pH 
environment (Fig. 5-5, a-b). In the absence of concanamycin A, acridine orange 
staining in the organelles peripheral to the nucleus is red (Fig. 5-5, a); after the 
addition of concanamycin A, red fluorescence is significantly reduced (Fig. 5-5, 
b), suggesting the reagent is inhibiting organellar acidification in these cells. We 
then added doxorubicin to concanamycin A-treated cells, and found that 
doxorubicin-sequestration was unaffected (Fig. 5-5, c-e). Thus, in HeLa cells 
over-expressing MRP1, alterations in cellular pH were unable to alter doxorubicin 
distribution, a finding in contrast with MCF7-Adr cells (Fig. 5-1, c) which have 
no doubt developed many different mechanisms of drug resistance during their 
protracted drug selection. 
To determine whether the co-localization of doxorubicin and MRP1 in 
intracellular compartments was mediated by MRP1 activity, we inhibited MRP1 
activity with verapamil, and then observed the distribution of doxorubicin. As 
expected, verapamil-treated cells accumulated doxorubicin primarily in the 
nucleus (Fig. 5-5, f-h), regardless of the degree to which they expressed MRP1-
ECFP. More interesting however was the almost total absence of peri-nuclear 
doxorubicin in these cells (Fig. 5-5, g). As a result of inhibiting MRP1 activity, 
doxorubicin accumulation in the nuclear periphery was also blocked, and MRP1-
ECFP cells treated with verapamil had no more vesicular doxorubicin 
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accumulation than cells not transfected with MRP 1-ECFP (Fig. 5-5, i). 
These results suggest that the expression of MRP 1-ECFP alone is responsible for 
the peri-nuclear accumulation of doxorubicin. 
We had now established that intracellular MRP 1-ECFP co-localizes with 
doxorubicin and that this co-localization is mediated by MRP1 activity. We next 
wanted to determine whether this intracellular MRP1 activity alone was sufficient 
to promote the classic doxorubicin-resistant phenotype: exclusion of the drug 
from the nucleus. We have seen that there are two pools of MRP 1, one at the cell 
surface, and one at the periphery of the nucleus. It is possible that the nuclear 
drug exclusion found in MRP 1-ECFP expressing cells is a result of MRP 1 activity 
at the surface of the cell. Although FACS analysis did suggest that MRP1 
expression only minimally, if at all, reduced the total doxorubicin uptake in HeLa 
cells (see chapter 4, Fig. 4-6, c), these data represent relationships on a log scale; 
less dramatic, but perhaps still physiologically relevant, decreases might be 
missed. Thus, it was still possible that MRP1 at the plasma membrane was 
reducing intracellular drug accumulation and this reduction alone was responsible 
for nuclear drug exclusion. Intracellular MRP 1 activity may have been unrelated 
to the decreased nuclear accumulation of the drug in MRP 1-expressing cells. 
To investigate this possibility, we needed a way of inhibiting MRP1 
activity only at the cell surface. With MRP1 blocked at the cell surface, we could 
then assay whether intracellular MRP1 could still sequester the drug in MRP1-
containing vesicles, and whether this activity was sufficient to decrease drug 
accumulation in the nucleus. For this purpose, we employed the help of two 
cysteine-based cross linking reagents, BM[PEO]4 and BMH. The first is a cell-
impermeable reagent which, if it blocked MRP1 activity, would do so only at the 
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cell surface, and in this way we would be able to isolate the activity of 
intracellular MRPl. The second would block both pools of MRP 1, if it inhibited 
MRP 1 at all. However, before using either cross-linking reagent, we needed to be 
sure that these reagents would block MRPl activity without impairing cell 
viability. If cells were viable after the administration of the cross-linkers, and if 
MRPl activity were inhibited by their administration, then these reagents would 
provide us a way of investigating the role of intracellular MRPl activity in 
nuclear drug exclusion. 
MRPl sensitivity to these reagents was gauged with the compound 
tetramethyl rhodamine ester (TMRE). TMRE is a fluorescent MDR substrate that 
does not accumulate inside MRPl-expressing cells, but instead, is effluxed from 
the cell in an MRPl-dependent manner. TMRE is also a live stain dye; drug entry 
is dependent on the maintenance of plasma membrane potential, and upon cell 
entry, TMRE accumulates in the mitochondria (Farkas et al, 1989). With TMRE, 
we could assay the effects of the cross-linking reagents on both cell viability and 
MRPl activity at the same time. If after addition of these reagents, TMRE 
entered all cells regardless of the degree to which they expressed MRPl, the 
cross-linking reagents could next be used to assay intracellular MRPl activity on 
doxorubicin. 
When cells were exposed to TMRE (Fig. 5-6, a-c), the MRPl-expressing 
cell (Fig. 5-6, a) accumulated little to none of the drug, while cells that did not 
express detectable levels of the MRPl-ECFP took up the drug in the mitochondria 
(Fig. 5-6, b-c). Treatment with the MRPl inhibitor verapamil rendered MRP1-
ECFP cells incapable of effluxing TMRE (Fig. 5-6, d-e), and all cells 
accumulated the dye in the mitochondria comparably (Fig. 5-6, f). These results 
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suggest that TMRE exclusion from the cell is mediated by MRPl. 
Crosslinking with the cell impermeable reagent BM[PEO]4 affected MRPl-ECFP 
expressing cells much as verapamil did; all cells accumulated TMRE to the same 
extent, regardless of the degree to which they expressed MRPl (Fig. 5-6, g-i). 
Likewise, when cells were cross-linked with the cell permeable reagent BMH, 
MRPl-dependent efflux of TMRE was also inhibited (Fig. 5-6, j-l). The fact that 
cells accumulated TMRE after the addition of either BMH or BM[PEO]4 suggests 
that cross-linking did not compromise cell viability. The fact that addition of 
these reagents inhibited MRPl-dependent TMRE transport suggests that cross-
linking is sufficient to block MRPl activity. Moreover, if BM[PEO]4 is only 
reacting with MRPl-ECFP at the cell surface, then these results indicate that 
MRPl activity at the plasma membrane is responsible for the absence of TMRE 
in cells. 
In order to determine whether BM[PEO]4 was inhibiting MRPl 
selectively at the plasma membrane, we next tested the effect of BM[PEO]4 
addition on sub-cellular pools of MRPl-ECFP. Because doxorubicin 
accumulates in MRPl- containing vesicles (Fig. 5-4, d-f), we tested the effect of 
BM[PEO]4 treatment on the intracellular distribution of the drug. Used in concert 
with BMH treatment, this experiment would test if BM[PEO]4 was inhibiting 
primarily plasma membrane MRPl and what role, if any, intracellular MRPl 
activity played in doxorubicin sequestration. 
When BM[PEO]4 treated cells were exposed to doxorubicin (Fig. 5-7, a-
c), doxorubicin did not accumulate in the nucleus of a cell expressing MRP1-
ECFP even though MRPl activity against TMRE is blocked with this treatment. 
Indeed, the MRPl-ECFP expressing cell (Fig. 5-7, a) continued to be 
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characterized by perinuclear doxorubicin staining (Fig. 5-7, b) which 
corresponds to the localization of intracellular MRPl (Fig. 5-7, a, c). In contrast, 
when cells were exposed to the cell permeable cross-linker BMH, prior to 
doxorubicin incubation (Fig. 5-6, d-f), all cells accumulated the drug within the 
nucleus, much as they did when treated with verapamil. These results reveal that 
BM[PEO]4 affected the activity of MRPl-ECFP primarily at the plasma 
membrane, whereas BMH inhibited MRPl throughout the cell. 
From these experiments, we can safely make the following observations. 
First, BMH and BM[PEO]4 do not affect cell viability. Second, MRPl activity at 
the surface of cells is responsible for the absence of TMRE accumulation in 
MRPl-expressing cells, and the addition of the cell impermeable BM[PEO]4 
blocks cell surface activity. Third, loss of cell surface MRPl activity upon 
BM[PEO]4 addition only marginally effects nuclear doxorubicin accumulation in 
MRP 1-expressing cells. Finally, only the additional loss of intracellular MRPl 
activity is sufficient to redistribute doxorubicin to the nucleus. These results then 
strongly suggest that intracellular MRPl is responsible for intracellular 
doxorubicin sequestration, a drug resistance phenotype. 
5.4 BM[PEO]4 and BMH cross-link MRP1-ECFP 
We next tested whether BMH and BM[PEO]4 are affecting MRPl activity 
by directly cross-linking MRPl-ECFP; if so, the electrophoretic mobility of 
MRPl should be altered by treatment with either reagent. When cell lysates of 
MRPl-ECFP transfected cells were immunoblotted with the anti-MRP 1 antibody 
MRPrl, the antibody recognized a doublet that migrated near a 250kDa protein 
standard. However, when cell lysates of BM[PEO]4 treated cells were similarly 
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probed, the antibody recognized a much more slowly migrating species 
of the protein, suggesting that the reagent was cross-linking MRPl directly. 
Likewise, when cell lysates of BMH treated cells were probed with the anti-
MRP 1 antibody, we see similar changes in the electrophoretic mobility of the 
protein (Fig. 5-8, a). We have reason therefore to believe that cross-linking with 
either reagent inhibits MRPl as a result of direct protein modification. 
5.5 BM[PEO]4 and BMH do not increase cell permeability to MRPl 
substrates 
Even if MRPl is being directly modified by these cross-linking reagents, it 
is possible that treatment with BM[PEO]4 or BMH is not inhibiting MRPl, but 
simply increasing cell permeability to TMRE. In order to investigate this 
possibility, we determined the average TMRE accumulation in a population of 
cells as a function of MRPl expression, and we determined whether this average 
was altered by the addition of cross-linker (Figure 5-8, b). When we calculated 
these averages, we found that neither BM[PEO]4 nor BMH had any effect on 
TMRE accumulation in cells that expressed MRPl-ECFP at background levels. 
We did find, however, that BM[PEO]4 was able to block MRPl activity on 
TMRE almost entirely; all BM[PEO]4 treated cells accumulated TMRE 
equivalently, even at high levels of MRPl expression. On the other hand, BMH 
inhibition of MRPl activity was not complete at the concentration of BMH used 
(Figure 5-8, b). However, since BMH enters cells and is free to interact with 
many intracellular cysteines, it might be more difficult to inhibit MRPl activity 
with BMH at a concentration that would not at the same time be lethal to the cells. 
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We next performed statistical analyses on BM[PEO]4-treated 
cells that were exposed to doxorubicin. We found that the concentration of the 
cell impermeable crosslinker that was able to block MRPl activity on TMRE had 
a marginal effect on doxorubicin distribution. After treatment with BM[PEO]4, 
MRPl-ECFP expressing cells still showed a statistically significant reduction in 
nuclear drug accumulation, if not as much as untreated MRPl-ECFP cells (Fig. 5-
8, c). In contrast, when cells were treated with BMH, the nuclear fluorescence of 
the drug was not reduced by the expression of MRPl-ECFP, as it was in control 
cells (Fig. 5-8, c). Thus, at a concentration of BMH that was only partially able to 
block MRPl-mediated TMRE efflux, MRPl activity against doxorubicin was 
inhibited. Since BM[PEO]4 treatment completely inhibited MRPl-ECFP activity 
at the plasma membrane, as assayed by loss of TMRE efflux, but had little effect 
on the sub-cellular localization of doxorubicin, we have reason to believe that the 
intracellular pool of MRPl-ECFP unaffected by BM[PEO]4 treatment is 
responsible for doxorubicin sequestration. 
5.6 Expression of Pgp and BCRP also results in analogous doxorubicin 
sequestration 
If the intracellular activity of MRPl is capable of mediating drug 
sequestration and thus presenting a drug-resistance phenotype, we wondered 
whether other MDR proteins would also be able to function in this way. We have 
already seen that BCRP and Pgp, for example, are expressed in compartments 
peripheral to the nucleus, in regions that are positive for lysosomal markers (Fig. 
5-9, a-c, and Fig. 5-9, g-i). Therefore, we decided to test the effect of expressing 
these proteins on doxorubicin accumulation. When BCRP-ECFP-transfected cells 
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were incubated in the drug, we found once again that doxorubicin 
accumulated in the nucleus of non-expressing HeLa cells. However, the 
expression of BCRP-ECFP (Fig. 5-9, d) redistributed the drug away from the 
nucleus into BCRP-positive vesicles (Fig. 5-9, e-f). In a similar fashion, Pgp-
expressing vesicles that were positive for lysosomal markers (Fig. 5-9, g-i) also 
accumulated doxorubicin (Fig. 5-9, j-l), and this accumulation correlated with loss 
of nuclear doxorubicin fluorescence. For these reasons, we suspect that 
intracellular Pgp and BCRP also function to sequester doxorubicin from the 
nucleus in peri-nuclear vesicles. However, more thorough examinations of the 
intracellular activity of Pgp and BCRP have yet to be performed. 
5.7 Discussion 
We have demonstrated that the plasma membrane transporter MRPl has a 
sub-cellular localization from which it can promote a drug resistance phenotype. 
This phenotype is reversible upon inhibition of MRPl by verapamil but 
unaffected by alterations in intracellular pH. Using fluorescent markers for the 
ER, the Golgi, the recycling endosomes, and the lysosomes, we have shown in the 
previous chapter that this intracellular MRPl activity most likely originates from 
the lysosomes. Moreover, Pgp and BCRP also localize to lysosomal membranes 
from which they also transport doxorubicin. 
Of course, MRPl activity does not stem entirely from the intracellular 
organelles; TMRE, for example, is effluxed by MRPl before it can accumulate in 
the cell, presumably by plasma membrane localized versions of the transporter. 
Strangely, the dominant activity of the protein on doxorubicin is on intracellular 
membranes. Our results suggest that MRPl may have different activity profiles at 
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different membranes, a difference that could be a function of 
environment (lipids, cholesterol) or post-translational modifications (e.g., 
phosphorylation) that occur at some sub-cellular compartments. Alternatively, 
these sub-cellular compartments may contain other transport mechanisms that act 
synergistically with MRPl activity. 
Intracellular localization and activity for MRPl and for other members of 
the MDR transporter family may suggest different strategies for chemotherapeutic 
regimens in a clinical setting. To date, inhibitors for these MDR transporters have 
been selected presumably on the assumption of plasma membrane based efflux 
mechanisms. MRPl-mediated intracellular drug sequestration may necessitate 
alternate strategies in the search for MDR inhibitors. 
Figure 5-1 Doxorubicin sequestration in MCF7-Adr cells, a-b. Doxorubicin is 
sequestered away from the nucleus, the target of doxorubicin toxicity, into acidified 
organelles in drug resistant MCF7-Adr cells (a), but not in the drug sensitive parent cell 
line M C F 7 (b). c. Disrupting organellar acidification with concanamycin A, an inhibitor 
of vacuolar-type proton ATPases, redistributes doxorubicin into the nucleus of MCF7-
Adr cells, suggesting the involvement of pH in drug sequestration, d. Inhibiting M R P 1 
and Pgp with verapamil also redistributes doxorubicin into the nucleus of MCF7-Adr 
cells, perhaps suggesting the additional involvement of these proteins in drug 
sequestration, e. In M C F 7 Adr cells, doxorubicin (first micrograph) accumulates in 
regions positive for the lysosomal marker synaptotagmin VII (second micrograph), an 







e M C F 7 A d r in D o x o r u b i c i n 
M R P 1 - E C F P D o x o r u b i c i n M e r g e 
Figure 5-2 The expression of M R P 1 in drug sensitive M C F 7 cells, a-c. 
The expression of MRP1-ECFP redistributes doxorubicin away from the 
nucleus and mimics a drug resistance phenotype in this drug-sensitive M C F 7 
line. d-e. An enlarged view of M C F 7 cells expressing MRP1; note the 
accumulation of the drug in MRP1-positive regions of the cell (arrow). 
Figure 5-3. Doxorubicin redistribution upon the expression of M R P L 
a-c. HeLa cells transfected with the lysosomal marker synaptotagmin VII 
are imaged after doxorubicin incubation. Doxorubicin accumulates in the 
nucleus and, to a much lesser extent, in vesicles at the periphery of the 
nucleus, d-f. A close up of the cell presented in (a-c), showing doxorubicin 
accumulation in peri-nuclear vesicles. These vesicles do not appear to co-
localize with the lysosomal marker; however, this is just a preliminary 
assessment, and the question needs further investigation, g-i. Significant 
enrichment of doxorubicin occurs in the peri-nuclear region of the cell as a 
result of MRP1-ECFP expression, and this enrichment appears to be in 
regions positive for MRP1-expression. 
Figure 5-4 Doxorubicin localizes to MRP1-ECFP-positive vesicles, a. E C F P 
fluorescence reveals that a transiently transfected HeLa cell expresses M R P 1 both at 
the plasma membrane and in a juxtanuclear region. The scale bar is 10pm. b. 
Doxorubicin fluorescence demonstrates that the drug likewise accumulates in a peri-
nuclear region in an MRP-ECFP expressing cell, while the non-expressing cells 
surrounding it accumulate the drug in the nucleus, c. The merge of MRP1-ECFP 
fluorescence (green) and doxorubicin fluorescence (red) shows the co-localization of 
doxorubicin and peri-nuclear localized MRP1-ECFP (yellow), d-f. An enlarged image 
of the cell depicted in (a-c) reveals individual MRP1-ECFP containing vesicles that 
also contain doxorubicin. The scale bar is 1pm. g-i. In rare instances when M R P 1 -
ECFP aberrantly collects in the endo-membrane system, doxorubicin accumulation is 
not peri-nuclear but is likewise dispersed. The scale bar is 10pm. j-l. A cell expressing 
low levels of MRP1-ECFP has little to no plasma membrane E C F P fluorescence and 
accumulates doxorubicin in a pattern that coincides with intracellular MRP1-ECFP 
The scale bar is 5pm. 
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Figure 5-5 Accumulation of doxorubicin in MRP1-positive regions is dependent 
on M R P 1 activity, and not pH. a-b. Acridine orange staining reveals concanamycin A-
dependent disruption of organellar acidification. Acridine orange fluoresces red in low 
pH environments. Upon the addition of concanamycin A, an inhibitor of V-type proton 
ATPases, HeLa cells show significant decreases in red fluorescence (acidified 
compartments), c-e. The disruption of organellar acidification with concanamycin A 
has no discernable effect on the distribution of doxorubicin in MRP1-ECFP expressing 
HeLa cells, f-h. Inhibiting M R P 1 activity with verapamil redistributes doxorubicin into 
the nucleus of MRP1-ECFP expressing HeLa cells, and substantially reduces peri-
nuclear accumulation of the drug. i. A non-transfected HeLa cells accumulates 
doxorubicin in a pattern very similar to MRP1-ECFP expressing cells treated with 
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Figure 5-6. Crosslinking MRP1-ECFP interferes with its ability to 
transport substrates at the plasma membrane, as assayed by T M R E 
accumulation, a-c. MRP1-ECFP expression prevents the intracellular 
accumulation of T M R E , so that the M R P 1 positive cell is not visible under 
T M R E fluorescence, d-f. Inhibiting M R P 1 with verapamil prevents M R P 1 -
mediated T M R E transport, and the two MRP1-ECFP expressing cells in this 
field now accumulate the drug. g-i. Crosslinking cells with the cell-
impermeable reagent BM[PEO]4 prevents MRP1-mediated T M R E transport so 
that the M R P 1 positive cell accumulates T M R E just like its non-expressing 
counterparts, j-l. Addition of the cell permeable crosslinker B M H also inhibits 
M R P 1 transport of T M R E . The scale bar for the micrograhps is 10pm. 
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Figure 5-7 MRP1-ECFP actively sequesters doxorubicin in internal 
compartments, a-c. Addition of the cell-impermeable cross-linker BM[PEO]4 has no 
effect on the sub-cellular distribution of doxorubicin in MRP1-ECFP expressing cells; 
the drug is still to be found in peri-nuclear regions positive for MRP1-ECFP. d-f. 
Addition of the cell-permeable crosslinker B M H redistributes doxorubicin to the 
nucleus of MRP1-ECFP expressing cells, much as the M R P 1 inhibitor verapamil does 
(g-i). 
Figure 5-8 The effect of crosslinking on the electrophoretic mobility and 
transport activities of MRP1-ECFP. a. In an immunoblot of MRP1-ECFP 
transfected cell lysates, an anti-MRP1 antibody recognizes a doublet whose 
molecular mass migrates below the 250kDa protein marker. However, addition of 
BM[PEO]4 significantly retards the mobility of MRP1-ECFP. An immunoblot of B M H 
treated cells likewise reveals a changed mobility of the protein after crosslinking. b. 
MRP1-ECFP activity can be quantified by relating how much T M R E a cell 
accumulates to how much MRP1-ECFP a cell expresses. Fluorescence functions as 
a reporter for both M R P 1 expression and T M R E accumulation. Neither BM[PEO]4 
nor B M H increase the permeability of cells to T M R E , since all cells with background 
M R P 1 fluorescence accumulate comparable levels of T M R E . Moreover, cells treated 
with BM[PEO]4, regardless of the degree to which they express MRP1, accumulate as 
much T M R E as untreated, non-MRP1 expressing cells, c. MRP1-ECFP activity 
against doxorubicin can be quantified by relating M R P 1 expression to the doxorubicin 
fluorescence inside the nucleus. In BM[PEO]4 treated cells, MRP1-ECFP still 
reduces the relative amount of doxorubicin accumulated in the nucleus. For both 
BM[PEO]4 treated and untreated cells, MRP1-mediated reduction in nuclear 
fluorescence is statistically significant (P< 0.01 and P<0.0001, respectively). 
However, all B M H treated cells have similar amounts of doxorubicin in the nucleus, 
whether they express MRP1-ECFP or not. 
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Figure 5-9 Pgp and B C R P co-localize with a lysosomal marker and 
accumulate doxorubicin in regions positive for either Pgp or BCRP. All scale 
bars represent 10pm. a. A cell transfected with BCRP-ECFP expresses the 
protein at the plasma membrane and in intracellular regions. The image is a 
deconvolved fluorescent section of a cell. b. Fluorescent dextrans chased into 
the lysosomes of the cell in a accumulate in intracellular vesicles, c. The merge 
of (a) and (b) shows the degree to which BCRP-ECFP (green) colocalizes with the 
lysosomal marker (red), d-f. Panel shows the degree of colocalization of BCRP-
ECFP in (d) and doxorubicin in (e). g-i. Panel shows the degree to which Pgp-
ECFP accumulates in intracellular vesicles (g) that are positive for fluorescent 
dextrans chased into the lysosomes (h). j-l. Panel shows the localization patterns 
of Pgp-ECFP and doxorubicin. 
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6 Chapter 6 MRPl activity and glutathione 
6.1 Glutathione co-transport model 
Previously published reports have suggested that MRPl-mediated 
transport of chemotherapeutic agents is dependent upon the presence of reduced 
glutathione. A number of lines of enquiry have suggested glutathione 
involvement in MRPl activity: in vitro studies with membrane vesicles derived 
from MRPl-expressing cells, in vitro transport assays with MRPl reconstituted 
into proteo-liposomes, as well as whole cell drug sensitivity assays with the 
glutathione-depleting agent BSO. These assays have all suggested that MRPl, a 
protein belonging to an organic anion transport family, needs the organic anion 
glutathione to activate the transport of hydrophobic, cationic chemotherapeutic 
drugs like daunorubicin or vincristine. In their protein reconstitution studies of 
MRPl, Mao et al., for example, found that glutathione stimulated the transport of 
radio-labeled vincristine by over 4 fold (Mao et al, 2000). In their examination 
of MRPl transfected cells, Zaman et al. observed that glutathione depletion with 
BSO resulted in a significant reduction in the IC50 values of doxorubicin and 
daunorubicin, 5 fold and 3 fold decreases, respectively (Zaman et al, 1995). 
Glutathione has been shown to stimulate the ATPase activity of the reconstituted 
protein (Hooijberg et al, 2000), and a photo-activatable derivative of glutathione, 
azido-phenacyl-glutathione, photo-labels the protein specifically (Qian et al, 
2002). In addition, enhanced glutathione transport has been measured in MRP1-
containing cells and membrane vesicles, especially in the presence of a drug 
substrate. 
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This data has led many to suggest a model of MRPl activity in 
which reduced glutathione promotes high affinity drug binding to MRPl. Upon 
binding to MRPl in the presence of glutathione, the drug is then co-transported 
from the cell with glutathione. This glutathione co-transport model has been 
evoked to explain MRP 1-mediated transport of the xenobiotics frequently used in 
chemotherapeutic regimens. For endogenous molecules speculated to be the 
physiological substrates of MRPl transport, however, the protein is not always 
thought to require glutathione for its activity. LTC4, for example, has been shown 
to be transported in the absence of glutathione, both in membrane vesicles and in 
proteoliposomes. The conjugated estrogen derivative 17-P-Estradiol 17-(P-D-
Glucoronide), also a putative physiological substrate for MRPl, is also not 
thought to require glutathione for its transport. These observations have led some 
to speculate that reduced glutathione is necessary to activate the transport of 
hydrophobic, cationic substances (Feller et al, 1995a). Indeed, the observation 
that calcein, itself an MRPl substrate, does not depend on reduced glutathione for 
its efflux from the cell, suggested this functional difference: glutathione activates 
the transport of only those substances that are non-anionic and not conjugated to 
organic anions (Feller et al, 1995a) 
However, there are some problems with this assessment of MRPl activity. 
Recent studies involving the conjugated estrogen estrone-3-sulfate (Qian et al, 
2001), as well as a p-O-Glucuronide conjugate of 4-(Methylnitrosamino)-l-(3-
pyridyl)-l-butanol (NNAL) (Leslie et al, 2001), have suggested that these anion 
conjugates also require glutathione for MRPl-dependent transport. In the case of 
estrone3-sulfate, transport at Vmax was stimulated a little over 4 fold by the 
i^napier o iviru-i anu glutathione 99 
presence of 1 mM glutathione; in the case of NNAL-O-glucoronide, 
maximal stimulation occurred at 3mM glutathione, both of which are within the 
range of intracellular glutathione for the average mammalian cell, l-5mM. While 
MRPl shows a glutathione requirement for estrone-3-sulfate transport (Qian et 
al, 2001), the protein does not need glutathione to transport the anionic estrogen 
conjugate, 17-p-Estradiol 17-(P-D-Glucoronide) (Loe et al, 1996a). Why would 
MRPl require the presence of reduced glutathione to transport some conjugated 
anions and not others? No model of MRPl activity to date has been able to 
address this question. Moreover, in the case of those anionic conjugates that are 
transported only in the presence of glutathione, no glutathione co-transport was 
observed. Neither estrone-3-sulfate nor NNAL-O-glucoronide were able to 
stimulate the transport of glutathione. If the glutathione co-transport model is 
correct, and glutathione is being effluxed out of the cell with MRPl substrates, 
then these substrates should reciprocally stimulate glutathione transport. Why 
glutathione would stimulate one class of substrates in accordance with the co-
transport model, and stimulate other drugs without being co-transported has not 
been addressed or resolved. 
6.2 Glutathione co-transport: evaluating the data 
A number of other questions also arise in reviewing the model of 
glutathione-dependent substrate transport. Much of the data supporting the model 
has been derived from kinetic measurements of protein activity in membrane 
vesicles or in proteo-liposomes. The assessment that glutathione is required for 
MRPl transport of chemotherapeutic agents, for example, is based on the finding 
that reduced glutathione increases transport rates several fold. However, even in 
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the presence of reduced glutathione, these transport rates are 
themselves quite low, and do not reflect transport rates found for other transport 
proteins. Moreover, the transport rates suggested for high affinity substrates are 
also extremely low and are not within a physiological range. Mao et al., for 
example, report that purified MRPl reconstituted into liposomes transports its 
high affinity substrate LTC4 with a Vmaxof 125 pmol/mg MRPl /min. At this 
rate, one molecule of MRPl would transport one molecule of LTC4 every 42 
minutes (Table 6-1). Moreover, the rate for vincristine transport in the presence 
of glutathione is 19 pmol/mg MRPl/min, a rate that would correspond to one 
molecule of MRPl transporting one molecule of vincristine every 4.6 hours 
(Table 6-1). The rate provided for vincristine transport is not suggested to be the 
maximal velocity of the protein, but it is the only one provided. These transport 
rates are not comparable to the transport rates of other ATPases or even other 
ABC transporters like P-glycoprotein (Table 6-2). Moreover, the rates of ATP 
hydrolysis derived for purified MRPl are either also low (Table 6-3, Cole), or 
correspond to non-physiological rates of substrate transport (Table 6-3 Riordan). 
Transporters that couple substrate transport to ATP hydrolysis are generally 
believed to transport 1 to 1,000 substrate molecules/sec. The transport rates 
available for MRPl in proteoliposomes seem to suggest then that the protein 
being studied has lost substantial activity during purification and reconstitution. 
The transport rates provided for MRPl in membrane vesicles are more 
difficult to interpret. Although each transport rate is provided at maximal velocity 
(Vmax), no attempt is made to assess the total MRPl concentration in the assays. 
Assessments of transport are instead provided in terms of transport velocity per 
total milligram of vesicle protein (Table 6-4). Therefore, we cannot determine 
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whether estimated transport rates could be within a physiological 
range. However, if we were to estimate that MRPl protein levels in their over-
expression system constitute between 0.1 and 1% of the total vesicle protein (a 
conservative estimate for an over-expression system), then their transport rates 
would be non-physiological for many of the substrates assayed, including those 
used to invoke the glutathione co-transport model (Table 6-4). 
Whole cell studies which conclude that MRPl is dependent on glutathione 
for its activity are problematic, as well. For example, in their study of MRPl-
mediated drug resistance in SI cells over-expressing MRPl, Zaman et al. do 
report a reduction in the IC50 values of both doxorubicin and daunorubicin upon 
the addition of the glutathione-depleting agent BSO (Zaman et al, 1995). 
However, similar reductions in the IC50 values for these two drugs were seen in 
Pgp-over-expressing SI cells in the presence of BSO, and this pattern was also 
evident in the SI background cell line. This discrepancy is noted in their study; 
however, no attempt was made to reconcile the non-specific effects of BSO with 
the model of MRPl glutathione dependence. 
6.3 Methods of studying glutathione dependence in vivo 
For all of these reasons, we have decided to investigate further the role of 
glutathione in modulating MRPl activity, using our fluorescent model system. 
Two ways of assessing glutathione dependence were available to us. The first 
was to examine the effect of BSO on cells over-expressing MRPl-ECFP. The 
second was to examine the effects of over-expressing MRPl on cells that had no 
endogenous glutathione biosynthetic pathway. Both assays would study the effect 
of glutathione depletion on MRPl activity; the former would examine the 
Uhapter o MKi' i ana glutathione 102 
question pharmacologically, the latter genetically, with a cell line 
generated from a mouse homozygous for a disruption in the gene encoding 
y glutamylcysteine synthetase (y-GCS). The y-GCS enzyme catalyzes the first 
step in glutathione synthesis (Fig. 6-1 a), and the loss of this gene product results 
in the complete loss of intracellular glutathione, as determined by HPLC (Shi et 
al, 2000). Although disruption of the y-GCS promoter and the first exon is 
homozygous lethal in the mouse, cell lines were established from the homozygous 
embryo at embryo day 3.5, five days prior to the average time of death (see Fig. 
6-1 b). These cell lines could only survive in the presence of exogenously added 
GSH or the reducing agent N-acetyl cysteine (NAC). Those cell lines maintained 
in NAC were dubbed GCS-NAC by Shi et al, indicating both the loss of the 
y-GCS gene product, as well as supplementation with NAC. 
To assess the activity of MRPl in the absence of cellular glutathione, we 
obtained the GCS2-NAC cell line and continued to maintain it in culture media 
supplemented with NAC. To ensure that this cell line had a disruption in the gene 
encoding the heavy subunit of y-GCS, we performed nested PCR on genomic 
DNA isolated from GCS2-NAC, using primers suggested by Shi et al. In this 
fashion, we confirmed that this cell line did contain a disruption in the y-GCS 
gene (Fig. 6-2, a). Next, we wanted to ensure that this disruption would result in 
the loss of glutathione production, as previously reported. For this purpose, we 
employed thin layer chromotography (TLC) to detect intracellular glutathione, 
using an assay commercially available from Molecular Probes. This glutathione 
detection assay chemically conjugates cellular glutathione to a fluorescent probe 
that can be visualized with TLC. The assay is sensitive to concentrations of 
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reduced glutathione within lOuM. When samples from GCS2-NAC 
cells were dotted onto the TLC plate, we found there to be no detectable 
glutathione, in accordance with the previously published report (Shi et al, 2000) 
(Fig. 6-2, b). 
6.4 Testing human MRPl activity in mouse 
Before expressing MRPl-ECFP in this glutathione null background, we 
wanted to ensure that the human gene encoding MRPl would be expressed and 
properly localized in a mouse embryonic stem cell line. For these sets of 
experiments, we used the BDC1 cell line, a mouse cell line derived from a wild-
type embryo, also at embryonic day 3.5 (Shi et al, 2000). The expression of 
MRPl-ECFP in this mouse line resulted in a sub-cellular protein distribution 
pattern similar to that seen in HeLa cells (see chapter 4). MRPl-ECFP localized 
to the plasma membrane (Fig. 6-3, a-b), and to an intracellular region that was 
predominantly perinuclear (Fig. 6-3, c-d, see also Fig. 5-2). To ensure that 
MRPl-ECFP retained activity in a mouse cell line, we incubated BDC1 cells 
expressing MRPl-ECFP in the MRPl substrate TMRE. Cells expressing the 
protein (Fig. 6-3, e) were able to exclude the drug and were negative for TMRE 
fluorescence (Fig. 6-3, f-g), indicating that the protein retained activity in this 
genetic background. 
6.5 MRPl is active in GCS2-NAC cells, in the absence of glutathione 
We could now test the activity of MRPl-ECFP in the GCS2-NAC cell line 
and thereby assess the glutathione dependence of MRP 1. We began with TMRE, 
a positively-charged, MRPl substrate that is also an indicator of cell viability. 
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When GCS2-NAC cells were exposed to TMRE, cells that did not 
express MRPl-ECFP readily took up the drug (Fig. 6-4, a). The observation that 
GCS2-NAC cells could be positive for TMRE indicates that the loss of 
glutathione had not compromised cell viability. Only the cell expressing MRP1-
ECFP was characterized by reduced TMRE accumulation (Fig.7-4, b-c). This 
MRPl-dependent reduction is made clear in a line scan of the fluorescent 
intensities of the field, where red represents TMRE and green represents MRP1-
ECFP fluorescence (Fig. 6-4, d). The observation that MRPl-ECFP expression is 
sufficient to reduce TMRE accumulation in GCS2-NAC cells suggests that MRPl 
can function in the absence of glutathione on at least one of its cationic substrates. 
The glutathione co-transport model has been evoked to explain MRPl-mediated 
transport of non-anionic substrates (Feller et al, 1995b). 
We next assayed the activity of MRPl against daunorubicin, a substrate 
previously thought to require glutathione for its transport from the cell (Zaman et 
al, 1995;Renes et al, 1999). Once again, GCS2-NAC cells showed MRP1-
dependent daunorubicin exclusion (Fig. 6-4, e-g), and had significantly reduced 
levels of intracellular daunorubicin relative to neighboring cells (Fig. 6-4, h). 
These experiments suggested that MRPl did not require glutathione to transport 
daunorubicin either. 
Finally, we tested the activity of MRPl-ECFP against vincristine, the 
substrate whose transport had been originally used to suggest the model of 
glutathione co-transport. Because vincristine is not fluorescent, we assayed drug 
transport by the degree to which microtubules were depolymerized after 
incubation in vincristine. We have seen previously that the expression of MRPl-
ECFP protects the cell from vincristine-induced microtubule loss (Chapter 4). 
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When GCS2-NAC cells were incubated in vincristine, MRPl-ECFP 
expression substantially mitigated the effects of the drug. MRPl-ECFP cells 
retained visible microtubule structure, with the microtubule organizing center 
readily identifiable (Fig. 6-4, i-k). 
In order to make a more statistical appraisal of MRPl activity in the 
absence of glutathione, we next quantified the accumulation of MRPl-substrates 
as a function of drug fluorescence, this time using large populations of GCS2-
NAC cells. We found that MRPl over-expression led to a statistically significant 
reduction in the accumulation of TMRE (Fig. 6-5, a) (P < 0.001). On average, 
TMRE fluorescence was reduced by a little over 71% in this glutathione-deficient 
cell line by the expression of MRPl-ECFP. Similarly, the expression of MRPl-
ECFP also led to a statistically significant reduction in the accumulation of 
daunorubicin in these cells (PO.001), decreasing daunorubicin fluorescence in 
ECFP-positive cells by slightly over 50%. Although these fluorescence-based 
assays may not correspond to direct assessments of intracellular drug 
concentrations, as a result of intracellular drug metabolism or fluorescence-
quenching, these assays do suggest that there is a pattern of differential drug 
accumulation upon MRPl-expression, and this pattern exists both in the presence 
and absence of intracellular glutathione. 
6.6 MRPl is active in cells pharmacologically depleted of glutathione 
We next sought to investigate the glutathione dependence of MRPl in 
cells treated with BSO, an irreversible inhibitor of the GCS holoenzyme. After 
incubation in BSO for prolonged periods of time, the glutathione bio-synthetic 
pathway is blocked and cells become depleted of their intracellular pools of 
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glutathione. BSO incubation protocols typically result in 80-90% 
reduction in intracellular glutathione after at least 24 hours of BSO exposure 
(Mans et al, 1992). In one study in which MRPl activity was said to be 
dependent upon glutathione, BSO treatment resulted in the loss of, on average, 
over 82% of intracellular glutathione stores (Zaman et al, 1995). When we 
incubated both HeLa and wild-type mouse embryonic stem cells in BSO 
following a similar protocol (see Chapter 2), we found that glutathione stores 
were likewise effected. HeLa cells, as well as BDC1 cells, experienced a greater 
than 80%o reduction in intracellular glutathione after BSO treatment (Fig. 6-6 a, 
b). 
We next assayed MRPl activity in BSO-treated HeLa cells against both 
TMRE and daunorubicin. The expression of MRPl-ECFP led to substantial 
decreases in the accumulation of TMRE, whether cells were treated with BSO or 
not (Fig. 6-7, compare a-d to e-h). Similarly, MRPl-ECFP expressing cells 
showed substantial reductions in daunorubicin accumulation relative to 
neighboring cells, despite the addition of BSO (Fig. 6-8, a-d vs. e-h). Statistical 
evaluations of large populations of MRPl-expressing cells also suggested that 
MRP 1 retained activity against both TMRE and daunorubicin after glutathione 
depletion via BSO (Fig. 6-9). Interestingly enough, these statistical assessments 
of BSO-mediated effects also suggested that BSO-treated cells accumulated more 
of the MRPl substrate, independent of MRPl expression (Fig. 6-9, a and b, 
compare the first two bars). TMRE and daunorubicin accumulation increased in 
cells expressing background levels of MRP1-ECFP by 64.8 and 112.8%, 
respectively (see Table 6-5). These results are in accordance with previously 
published results demonstrating the non-MRP 1-specific effects of BSO in 
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enhancing drug toxicity (Zaman et al, 1995). In our case, it seemed as 
if BSO might be making the cell more permeable to MDR substrates like TMRE 
and daunorubicin. 
6.7 BSO increases cell permeability to MDR substrates 
To test this possibility, we examined the effects of BSO on drug 
accumulation in cells endogenously expressing varied levels of MRPl (Fig. 6-10, 
a). The MCF-7 Adr cell line, for example, is multi-drug resistant, expresses both 
MRPl and Pgp, and has been selected for elevated resistance to doxorubicin, an 
anthracycline closely related to daunorubicin in structure. When MCF7-Adr cells 
were incubated in daunorubicin, we found that these cells had significantly 
elevated levels of drug accumulation in response to BSO-treatment (Fig. 6-10, b-
c). At the same light threshold levels, and under identical illumination conditions, 
BSO-treated cells had much greater daunorubicin fluorescence (Fig. 6-10, c) than 
untreated cells (Fig.7-10, c). On average, daunorbubicin fluorescence in MCF7-
Adr cells increased by 181.6% as a result of BSO (Fig. 6-11, a). TMRE drug 
incubation assays were more difficult to interpret in this cell line, as MCF7-Adr 
cells did not uptake TMRE, perhaps indicating the toxic effects of continual 
selection under doxorubicin (Fig. 6-10, d-e). We also assayed the effects of BSO 
on the primary NHDF line, whose endogenous expression of MRPl was the least 
elevated of the three cell lines tested (Fig. 6-10, a). When NHDF cells were 
incubated in TMRE, we found that TMRE fluorescence increased on average by 
179%o in response to BSO treatment (Table 7-5, Fig. 6-11, a). Finally, we 
attempted to assess the effect of BSO on drug uptake in non-transfected NIH 3T3 
cells, but shortly after exposure to BSO, this cell line rounded up and died (Fig. 6-
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11, c). We even examined the effect of BSO on the glutathione-null 
cell line, GCS2-NAC, and discovered that in this line, too, there was a BSO 
induced increase in drug accumulation (Table 7-5). Thus, in all cell lines tested, 
BSO had non-MRP 1 mediated effects on drug uptake and toxicity. 
6.8 Discussion 
Well established as an organic anion transporter with broad specificity 
(Leier et al, 1994; Loe et al, 1996a; Loe et al, 1996b; Hooijberg et al, 1999), 
MRPl has also been shown to transport cationic, and neutral hydrophobic 
compounds like the anthracyclines, vincrisitine, and TMRE (Cole et al, 199A; 
Grant et al, 1994; Paul et al, 1996; Rajagopal et al, 2002). Much speculation 
has surrounded the ability of the transporter to promote the cellular efflux of non-
anionic substances, and it is generally believed that compounds that are cationic 
or neutral in nature are co-transported with reduced glutathione. The model for 
glutathione co-transport has been suggested primarily by protein reconstitution 
assays in membrane vesicles and proteoliposomes (Loe et al, 1996b; Loe et al, 
1998; Mao et al, 2000; Loe et al, 2000), as well as by whole cell studies 
involving glutathione depletion via BSO (Zaman et al, 1995). Glutathione is 
speculated to facilitate the high affinity transport of non-anionic substances, either 
by inducing conformational changes in the protein (Qian et al, 2001) or by a 
mechanism that invokes positive co-operativity between drug binding and 
glutathione binding (Borst et al, 1999). 
When we examined the ability of MRPl to transport cationic substances in 
the absence of glutathione, however, we found that MRPl still retained activity 
against three of its substrates, TMRE, daunorubicin, and vincristine, substrates 
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which previously were thought to require glutathione for transport. In 
GCS2-NAC cells deficient in the production of y-gluatmyl cysteine synthetase, a 
gene necessary for glutathione production, MRPl expression resulted in protein-
dependent reduction of cationic substrates. Moreover, in BSO-treated HeLa cells, 
as well as in BSO-treated NHDF cells, MRPl expression also resulted in the 
cellular reduction of cationic substrates. Our data is not in accord with previous 
assessments of MRPl activity, and the basis for this disagreement is not clear. 
However, data published to date regarding the glutathione dependence of MRPl 
has been collected either in cell-free systems, in proteoliposomes or inside-out 
membrane vesicles, or in BSO-treated cells depleted of cellular glutathione. In 
vitro assessments of MRPl activity, though certainly indispensible for gathering 
basic biochemical data, may not represent the transport abilities of the protein in 
vivo. Moreover, our data indicate that when whole cells are depleted of their 
glutathione stores by treatment with BSO, these cells appear to be more 
permeable to MRPl substrates, an increase that cannot be explained by 
glutathione depletion alone, as GCS2-NAC cells also experienced this increase 
once treated with BSO. 
This BSO-mediated increase in cellular drug accumulation might help 
explain previously published observations that MRPl is inhibited by BSO. 
Indeed, comparison of drug accumulation in MRPl-expressing HeLa cells with 
and without BSO treatment (Fig. 6-9, a, bars 3-4 and Fig. 6-9, b, bars 3-4), might 
lead to the conclusion of an MRPl-specific effect; however, reference to the 
change in drug accumulation experienced by non-MRP 1 expressing cells (Fig. 6-
9, a, bars 1-2, and Fig. 6-9, b, bars 1-2) makes this possibility less likely. Non-
specific increases in drug accumulation were found in all four cell lines treated 
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with BSO, including GCS2-NAC cell lines. It is therefore also 
difficult to conclude that BSO is increasing cell permeability by depriving 
endogenous MRPl of glutathione, as GCS2-NAC cells have never biosynthesized 
glutathione. 
In demonstrating that MRPl can function in the absence of glutathione, 
we cannot discount the possibility that, if present, glutathione does support 
MRPl-mediated transport. It is entirely possible that under conditions in which 
glutathione is depleted, another cellular compound functionally substitutes for 
glutathione in enabling MRP 1 activity. This compound may facilitate 
conformational changes in MRPl that are redox dependent or it may be co-
transported with MRPl substrates. Whether another compound might be able to 
functionally substitute for glutathione or whether MRPl activity is independent of 
glutathione entirely should prove to be an important area of research for future 
investigation. 
Figure 6-1 Glutathione bio-synthetic pathway and generation of a glutathione 
deficient mouse line. a. Glutathione biosynthesis is catalyzed by two enzymes, y-
glutamylcysteine synthetase (y-GCS) and glutathione synthetase. Loss of the y-GCS 
enzyme or inhibition of enzyme activity via B S O results in the loss of glutathione 
production. This figure is adapted from Stryer's Biochemistry, b. A mouse embryo 
homozygous for the loss of the gene encoding the heavy subunit of y-GCS was 
generated by Shi et al. with a disruption in the TATA box and the first exon of the gene. 
The disruption was embryo lethal by embryo day 8.5, but cell lines were rescued at 
embryo day 3.5. Arrow pairs in the figure indicate primers used to confirm the gene 
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Figure 6-2 Confirmation of the disruption in y-GCS in G C S 2 - N A C cells, a. To 
confirm that the GCS2-NAC cells used in our experiments were deficient for glutathione 
synthesis, w e performed nested P C R on genomic GCS2-NAC and wild type BDC1 cells. 
The primers used for the results of the P C R reaction shown here are indicated as arrow 
pairs in Figure 6-1. Lanes 1, 6 are loaded with a 100 bp D N A ladder. Lane 2 is the wild 
type BDC1 genome probed with primers for the gene disruption. Lane 3 is the wild type 
BDC1 genome probed with primers for the wild-type sequence (removed by the gene 
disruption in mutant allelles). Lane 4 is the mutant GCS2-NAC genome probed using 
mutant primers. Lane 5 is the mutant GCS2-NAC genome probed using wild-type 
primers, b. Thin layer chromotagraphy was performed on GCS2-NAC and BDC1 cells 
to confirm that the former was deficient in glutathione production. The assay detects 
glutathione after chemical conjugation of reduced glutathione to a fluorescent substrate. 
Lane 1 (box) was loaded with glutathione that was pre-conjugated to the fluorescent 
substrate. Lane 2 was loaded with cell culture media and lysis buffer alone. Lane 3 was 
loaded with GCS2-NAC cell lysates. Lane 4 was loaded with BDC1 cell lysates. Sample 
size of lane 4 was half of that of lane 3. Arrow indicates non-conjugated fluorescent-
substrate. 
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Figure 6-3 MRP1-ECFP is expressed, properly targeted, and functional in a mouse 
cell line. a-b. MRP1-ECFP is targeted to the plasma membrane in BDC1 mouse cells. 
Arrows indicate the rim-staining characteristic of proteins localized to the plasma 
membrane, c-d. MRP1-ECFP is also found in a peri-nuclear region in BDC1 mouse 
cells, e-g. MRP1-ECFP expressing cells (e) have substantially reduced T M R E 
fluorescence (f) compared to neighboring cells. 
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Figure 6-4 M R P 1 is active in G C S 2 - N A C cells, a. Transiently transfected GCS2-
N A C cells incubated in T M R E showed cellular drug accumulation as a function of 
rhodamine fluorescence. The cell in the center showed decreased T M R E 
accumulation, b. An MRP1-ECFP expressing cell in this same field is revealed by 
E C F P fluorescence, c. The merge of E C F P fluorescence (green) and rhodamine 
fluorescence (red) revealed that M R P 1 expression correlated with decreased T M R E 
accumulation, d. A line scan of the fluorescent intensities in the merged image (c) 
illustrated MRP1-dependent T M R E reduction in these cells, e-h. MRP1-ECFP 
transfected cells showed decreased daunorubicin accumulation as a function of 
M R P 1 -expression, i-k. MRP1-expression correlated with chemo-protection against 
vincristine-mediated microtubule damage. 
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Figure 6-5. Quantification of MRP1-dependent drug transport in 
glutathione depleted cells, a. MRP1-ECFP transfected GCS2-NAC 
cells showed MRP1-dependentTMRE reduction, where cells expressing 
M R P 1 are identified by "above background" E C F P fluorescence, b. 
G C S 2 - N A C cells also showed an M R P 1 -dependent reduction in 
daunorubicin accumulation. The reduction in drug accumulation seen 
with M R P 1 -expression was statistically significant for both T M R E and 
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Figure 6-6 B S O incubation depleted intracellular glutathione stores by 
more than 8 0 % . a. HeLa cells were assayed by TLC for intracellular 
glutathione stores, both with and without treatment with BSO. Treatment with 
B S O decreased glutathione stores in these cells to nearly undetectable levels, 
comparable to the no cell control (compare bars 1 and 2). Glutathione levels 
are presented as a percentage of non-treated HeLa cells of a fixed sample size 
(bar 5). Glutathione levels decrease in non-treated samples with sample size 
(bar 3, bar 4). b. BDC1 cells were also assayed by TLC for glutathione both 
with and without B S O treatment. B S O reduced glutathione levels in BDC1 cells 
(bar 4) to levels comparable to the no cell control (bar 1) or GCS2-NAC cells (bar 
2-3). B S O had no effect on glutathione levels in GCS2-NAC cells (bars 2-3). 
Glutathione levels are expressed as a percentage of those found in wild type 
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Figure 6-8 M R P 1 is active against daunorubicin in H e L a cells depleted of cellular 
glutathione via B S O . a-d. A n MRP1-expressing HeLa cell (b) incubated in 
daunorubicin showed reduced drug accumulation compared to two non-MRP1 
expressing cells (a), as seen in the merged image (c) and in the line scan (d). e-h. 
B S O treated H e L a cells incubated in daunorubicin still showed MRP1-dependent 
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Figure 6-9. Quantification of MRP1-dependent drug transport in HeLa 
cells depleted of glutathione via BSO. a. BSO-treated HeLa cells 
transfected with M R P 1 showed MRP1-dependent T M R E reduction (bars 2 and 
4), just as non-BSO treated HeLa cells did (bars 1 and 3). B S O treatment 
increased T M R E accumulation in both MRP1-ECFP and non-MRP1-ECFP 
expressing cells (compare bars 1 and 2) b.Both BSO-treated and non-BSO 
treated HeLa cells showed an MRP1-dependent reduction in daunorubicin. 
B S O addition increased cellular accumulation of daunorubicin in cells 
independent of M R P 1 expression (compare bars 1 and 2). 




Figure 6-10. Evaluation of the effect of B S O on cells expressing varied 
levels of M R P L a. Western blots of HeLa (lane 1), N H D F (lane 2), and MCF7-
Adr (lane 5) cell lines reveal varied degrees of endogenous M R P 1 expression, 
compared to MRP1-ECFP transfected HeLa cells (lane 3). Similar sample sizes 
were loaded. Arrows indicate position of MRP1. Lane 4 is a protein weight 
standard, b-c. B S O increases the permeability of MCF7-Adr cells to doxorubicin; 
micrographs are set to identical light threshhold values, with identical exposure 
times, d-e. The effect of B S O on the permeability of MCF7-Adr cells to T M R E 
cannot be assessed, as T M R E does not enter these cells. 
Figure 6-11. B S O increases cellular drug accumulation and has cytotoxic 
effects in NIH3T3 cells, a. A multidrug resistant tumor cell line (MCF7-Adr) and a 
primary cell line (NHDF) showed BSO-dependent increases in daunorubicin 
accumulation, b. N H D F cells also showed BSO-dependent increases in T M R E 
accumulation, c. The cytotoxicity of B S O in NIH 3T3 cells is demonstrated by the 
sudden decrease of adherent cells after B S O addition. 
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Chapter 7 Conclusion 
In the previous chapters, we have presented an in vivo examination of 
MRPl activity which has, for the first time, investigated the role of the 
localization, substrate specificity, and co-factor dependence of MRPl on a single 
cell basis. With the construction of our fluorescent MRPl-EGFP reporter, we 
have been able to address specific questions about the effects of expressing the 
protein in living cells, without the use of drug selection. In the absence of drug 
selection, our model system has avoided up-regulating other drug response 
mechanisms whose contributions to drug resistance might easily be conflated with 
the activity of MRPl. In this way, we have been able to examine the effect of 
expressing only MRPl under different conditions: when using different cell lines 
or when using different putative substrates, in the absence of glutathione or in the 
presence of BSO. Our model system also allowed us to examine the effect of 
expressing other MDR-conferring proteins, either singly or pairs of them together, 
in the same cellular background and under the same culture conditions, and thus 
enabled more careful comparisons of the activity profiles of these proteins. 
Finally, the use of a fluorescent construct in single-cell assays allowed us to 
correlate degrees of protein expression to transport efficiencies on a cell per cell 
basis, an ability important for understanding thresholds of protein activity. 
This single cell approach was especially useful in studying the sub-cellular 
localization and activity of MRPl. Using this technique, we were able to discern 
differences in the sub-cellular distribution of MRPl in single cells expressing 
different levels of the protein. We saw cells for which the protein was 
predominantly in sub-cellular compartments, and cells for which the protein was 
^uiiuiusiun 
also significantly expressed at the plasma membrane. Using 
fluorescent markers for sub-cellular organelles, we were then able to identify 
MRPl-positive compartments during one stage in the trafficking history of the 
protein, and we were able to extend this localization to other multi-drug resistance 
proteins. Furthermore, we were able to correlate the sub-cellular expression of 
these proteins with patterns of drug accumulation, a task out of the range of other 
detection techniques (radio-labeled transport studies, immunocytochemistry and 
protocols requiring cell fixation). And, more importantly, with the use of cross-
linking reagents, we were able to show, on a single cell level, that the activity 
from these sub-cellular compartments was sufficient to mimic a drug resistance 
phenotype. 
Our model system was also useful in examining the dependence of MRPl 
activity on glutathione. We were able to compare the activity profiles of the 
protein in cell lines depleted for glutathione with cells whose glutathione 
biosynthesis pathways were not disrupted. Single-cell examinations of 
transfected cells incubated in BSO revealed to us that the addition of this 
glutathione depleting agent increased cell permeability to MDR substrates. We 
saw that this BSO-mediated increase was independent of MRPl activity, as 
GCS2-NAC cells genetically depleted of their glutathione stores also had 
increased cell permeability to MDR drugs upon BSO addition. These direct, side 
by side comparisons of cells both over-expressing and not over-expressing MRPl, 
of cells both treated and not treated with BSO, facilitated a more direct 
examination of MRPl dependence upon glutathione. As a result, we have seen 
that in multiple cell lines, and with different modes of disrupting glutathione 
synthesis, MRPl retains activity in the absence of glutathione. 
V^UIlClUMUIl ]3Q 
This assessment of glutathione independence for MRPl runs 
counter to many previously published examinations of MRPl activity, and we 
have no ready explanation for this disagreement. It is possible that in the absence 
of glutathione, the cell employs other organic anions to catalyze MRPl-mediated 
transport. There are reports, for example, that opthalmic acid can functionally 
substitute for glutathione in this capacity (Leslie et al, 2001). It is also possible 
that the in vitro activity of MRPl, as revealed by protein reconstitution studies 
and membrane vesicle transport assays, is not representative of the activity of the 
protein in whole cells. In the process of purifying and reconstituting the protein, 
for example, MRPl may have lost some of its activity; certainly, the transport 
rates reported for the protein would be consistent with this hypothesis. 
Other interesting avenues of investigation also remain open at the end of 
this study. It has not been determined, for example, whether the functional re-
expression of the GCS holoenzyme would affect MRPl-mediated transport in 
GCS2-NAC cells. We are of the opinion that any changes in MRPl activity 
would be attributable to enhanced cell viability in the presence of glutathione. 
However, these questions could be tested by using another MDR protein like 
BCRP in conjunction with MRPl. Additionally, it would be interesting to 
determine whether in GCS2-NAC cells, MRPl could transport conjugated organic 
anions, especially those conjugated anions that were previously thought to require 
glutathione for transport. Thus far, we have only tested the transport of cationic, 
hydrophobic substances like TMRE and daunorubicin in this cell line. 
Conjugated organic anions like estrone-3-sulfate nor NNAL-O-glucoronide may 
respond differently in this background. It might also be interesting to examine 
patterns of doxorubicin sequestration in these glutathione deficient cells, and test 
V^UU^lUMUll 131 
whether glutathione could play any role in the metabolism or vesicular 
accumulation of the drug. 
A number of questions are yet to be addressed with respect to the sub-
cellular localization and activity of MRPl, too. We have seen that in one period 
in its trafficking history, the protein resides in the lyososomal compartment. 
What secretory path does the protein follow to arrive at this compartment? Has 
lysosomal MRPl recently been endocytosed from the plasma membrane or has it 
followed the alternate ER-to-Golgi path to the lysosomes? Are there, then, two 
separate pools of the protein, one directed to the plasma membrane, and another 
to the lysosomes? Are there post-translational differences in these two pools or 
any other discernable method of segregating them? If there is only one pool of 
MRPl in these cells, is the lysosomal pool derived from recently endocytosed 
plasma membrane MRPl or is the plasma membrane MRPl derived from recently 
exocytosed lysosomal MRP 1 ? And with respect to the pool of lysosomal MRP 1, 
does the protein reside in multi-vesicular bodies within the compartment or is the 
protein capable of halting the multi-vesicularization associated with lysosomal 
degradation? 
We have seen that when MRPl-ECFP is weakly expressed in HeLa cells, 
MRPl is to be found primarily in sub-cellular compartments, and not at the 
plasma membrane at all. Is this sub-cellular MRPl also lysosomal or could it 
simply be protein associated with the Golgi or the ER? Moreover, we have only 
identified the sub-cellular compartment in one period in the trafficking history of 
the protein. Is the protein found predominantly in other sub-cellular 
compartments at other times? And is this trafficking history shared with other 
members of the MRP family? The apically-localized MRP2, for instance, has 
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been found to reside in a novel sub-cellular organelle in non-polarized 
hepatic cells (Tuma et al, 2002); to what extent would the baso-laterally localized 
MRPl also be found there if expressed in these cells? How much of the sub-
cellular trafficking history of MRPl is dependent upon cell and tissue type? 
Would the distribution of sub-cellular MRPl be dependent upon polarization? 
And in tissues, would protracted drug exposure have any effect on the localization 
of the protein? 
Questions also arise with respect to protein localization and doxorubicin 
resistance. It has been suggested, for example, that doxorubicin resistance in 
human MRPl is dependent upon a specific residue in the protein (glutamate at 
amino acid 1089). Mutations in MRPl at this residue sensitize otherwise resistant 
cells to doxorubicin, and the mouse ortholog, mrpl, which does not confer 
resistance to doxorubicin, also does not contain glutamate in the orthologous 
position. Moreover, mutations in mouse mrpl that result in glutamate 
conversions at this critical residue confer doxorubicin resistance (Zhang et al, 
2001). It would be interesting to see whether this residue, and patterns of 
doxorubicin resistance, are linked in any way to MRPl targeting and sub-cellular 
localization. If drug sequestration is an important means of conferring MRPl-
mediated resistance to doxorubicin, maybe residues in this region relay protein 
targeting information. Perhaps there are differences in the sub-cellular 
localization of mouse mrpl and human MRPl that affect drug sensitivity. 
Of course, there are a host of other problems and questions not directly 
addressed by the work presented in this thesis, such as the function of the protein 
in normal physiology, and the many changes that must occur, both in promoter 
regulation, and in protein trafficking, as a result of cellular transformation and 
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acquired drug resistance in whole organisms. Much work also remains 
to be done in the field addressing effective means of inhibiting MRPl-mediated 
drug resistance in a clinical setting. In all, the work presented in this thesis has 
addressed questions about MRPl trafficking and activity, substrate specificity and 
co-factor dependence, and has at the same time, served to elicit many more and 
interesting questions along the way. 
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